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A b s t r a c t  
 
Several biomarkers had been proposed as useful parameters to better define the 
prognosis or to delineate new target therapy strategies for glioblastoma (GBM) 
patients. MicroRNAs could represent interesting molecules, for their role in 
tumorigenesis and cancer progression and for their specific tissue expression. 
Although many studies have tried to identify a specific microRNAs signature for 
glioblastoma, by now an exhaustive GBM microRNAs profile is far to be well 
defined. 
In this work we set up a real-time qPCR, based on LNA primers, to investigate the 
expression of 19 microRNAs in brain tumors, focusing our attention on GBMs. 
MiRNAs expression in 30 GBM paired FFPE-Fresh/Frozen samples was firstly 
analyzed. The good correlation obtained comparing miRNAs results confirmed 
the feasibility of performing miRNAs analysis starting from FFPE tissues. This 
leads to many advantages, as a good disposal of archival tumor and normal brain 
specimens and the possibility to verify the percentage of tumor cells in the 
analyzed sample. In the second part we compared 3 non-neoplastic brain 
references to use as control in miRNAs analysis. Normal adjacent the tumor, 
epileptic specimens and a commercial total RNA were analyzed for miRNAs 
expression and results showed that different non-neoplastic controls could lead to 
important discrepancies in GBM miRNAs profiles. 
Analyzing 50 FFPE GBMs using all 3 non-neoplastic references, we defined a 
putative GBM miRNAs signature: mir-10b, miR-21 and miR-27a resulted 
upregulated, while miR-7, miR-9, miR-26a, miR-31, miR-101, miR-137, miR-222 
and miR-330 were downregulated. 
Comparing miRNAs expression among GBM group and gliomas of grade I, II and 
III, we obtained 3 miRNAs (miR-10b, mir-34a and miR-101) showing a different 
regulation status between high grade and low grade gliomas. Intriguingly, miR-
10b was upregulated in high grade and significantly downregulated in low grade 
gliomas, suggesting that could be a candidate for a GBM target therapy. 
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1.1 Gliomas: from classif ication to target treatments  
 
Malignant gliomas constitute the 80% of primary malignant brain neoplasia and, 
represent the most common lesions among all primary brain tumors, covering the 
30% of cases with a yearly incidence of 6 cases per 100,000[1]. 
Gliomas could arise from de-differentiated mature neural cells, neural stem cells 
or from progenitor cells [2, 3]. They are usually classified depending on 
histopatological histotype in astrocytomas, mainly composed by fibrillary or 
gemistocytic neoplastic astrocytes, oligodendrogliomas, composed by 
monomorphic cells with uniform round nuclei; mixed oligoastrocytomas, 
characterized by neoplastic glial cells with astrocytic or oligodendroglial 
phenotypes and ependymomas, mainly constitued by ependymal cells (Table 1.1). 
Only astrocytic tumors represent about the 75% of all gliomas, among them 
glioblastoma (grade IV) account for the 54% (Table 1.1) [1]. 
Gliomas are further divided in low grade (grade I and II) and high grade (grade III 
and IV) tumors depending on grade of malignancy (Table 1.2) [4].  
 
1.1 .1  Low grade gl iomas  
Low grade tumors are benign lesions, circumscribed to the brain, characterized by 
well differentiated cells and good prognosis. They are generally solved with the 
only surgery: although commonly the size of the lesions is relatively small, with 
indolent and slow growth, when the tumor arises in a critical area of the brain it 
could cause severe problems if not removed. In cases where the surgical removal 
is not possible or not decisive, radio- and chemo-therapy are also considered. 
Grade I gliomas are classified as follows: subependymal giant cell astrocytoma, 
pilocytic astrocytoma, as astrocytic lesions, and subependymoma and 
myxopapillary ependymoma, as ependymal tumors (Table 1.2) [3, 4]. 
Grade II gliomas account for about 25% of diffuse gliomas and they are still 
considered relative benign tumors: they are classified in pilomyxoid astrocytoma, 
diffuse astrocytoma and pleomorphic xanthoastrocytoma, for astrocytic lesions, 
oligodendroglioma, oligoastrocytoma and ependymoma (Table 1.2) [3, 4].  
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All of them are characterized by well differentiated cells, moderate cell density 
and occasionally anaplastic cells with nuclear atypia could be present [3].  
They present a propensity to infiltrate the surrounding brain parenchyma that lead 
surgery not always possible or decisive.  
In about the 70% of cases, a grade II glioma could progress to a lesion of higher 
grade of malignancy, related to the accumulation of genetic alterations [5].  
As regards the prognosis, it is reported that a patient affected by a WHO grade II 
glioma typically survive more than 5 years (6-8ys for grade II astrocytomas, 12ys 
for grade II oligodendrogliomas, 6ys for mixed oligodendroastrocytomas) [3, 4]. 
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Table 1.2. Classification of gliomas depending on histopatological histotype and grade of 
malignancy. 
 
1.1 .2  High  grade g l iomas  
Grade III gliomas constituted about the 25% of diffuse gliomas and they could 
present as primary lesions or secondary tumors derived from a grade II glioma, 
sharing the same histopathological phenotype [3]. Anaplastic astrocytoma, 
anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic 
ependymoma are grade III gliomas (Table 1.2), all of them are characterized by 
high proliferation rate, invasiveness and poor prognosis [3, 4].  
A regional or diffuse analpasia is present, cell density increases in comparison 
with a grade II, more nuclear atypias and mitotic activity are described.  
These anaplastic lesions are generally treated with conventional surgery, radio- 
and chemo-therapy. The median survival is about 3 years for anaplastic 
astrocytomas and mixed anaplastic oligoastrocytomas, while the oligodendroglial 
subtype has a better prognosis (3-10 years) [3, 4].  
Glioblastoma, giant cell glioblastoma, gliosarcoma and glioblastoma with 
oligodendroglial component are grade IV astrocytic gliomas, except for the latter 
one which present a mixed histotype (Table 1.2) [4]. Glioblastoma (GBM) is the 
most malignant and the most frequent brain tumor of the adult, accounting for 
about 50% of diffuse gliomas [3]. It is constituted by pleomorphic astrocytic 
tumor cells and it is characterized by poor cell differentiation, high cell density, 
marked nuclear atypia, high mitotic activity. Moreover, marked microvascular 
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proliferation and necrosis are peculiar features, in association with a high 
proliferation rate, marked invasiveness and resistance to chemo- and radio- 
therapies [3]. Glioblastoma could arise without an evidence of a precursor lower 
grade lesion (primary glioblastoma, which represent about the 90% of cases in 
older patients) or could progress from a grade II astrocytoma (secondary 
glioblastoma, about the 10% of cases with an average onset under 45ys) [3, 5]. 
Primary and secondary GBMs are indistinguishable from a histopathological point 
of view, but they are characterized by different molecular alterations (see 
paragraph 1.1.3 and Figure 1.2) [5, 6]. Depending on pathway alterations and 
gene expression profile, primary GBMs are further classified in four 
transcriptional subclasses: classic, neural, proneural, and mesenchymal [6, 7].  
Despite progresses in surgical techniques, radio-, chemo- and target therapies, the 
GBM prognosis remains poor, with a median survival less than one year [4, 8-10]. 
An early onset, prompt diagnosis, feasible surgical resection, adjuvant treatments, 
giant-cell or oligodendroglial subtypes are associated to a better prognosis [10]. 
 
1.1 .3  Molecular  c lass i f i ca t ion  o f  g l iomas  
A classification based on grading and histological features is not exhaustive to 
deeply characterize gliomas.  
In the last years several prognostic and predictive biomarkers were proposed, 
attending to explain the great variability in biologic behavior which characterizes 
each diagnostic category. For glioblastomas, for which the conventional therapies 
are not enough to contrast tumor progression and to ensure a better prognosis, the 
discovery of new genetic alterations could be useful to define potential molecular 
targets for developing specific treatments.  
Taking in consideration the classical classification of gliomas, they were further 
characterized according to their molecular alterations, often associated to specific 
histological subtype. The most common alterations described in low and high 
grade gliomas are listed below (when known, it is reported also the prognostic 
value of a particular alteration): 
- IDH1 mutations. Heterozygous IDH1 (isocitrate dehydrogenase 1) mutations 
(the most common one is the R132H substitution) are prognostic factors 
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associated to younger onset and longer overall survival. They are detected in 
grade II and III gliomas and in secondary glioblastomas (80%). It was also found 
in <10% of primary GBMs (Figures 1.1 and 1.2) [2, 3, 5, 6, 10]. 
 
 
Figure 1.1. Main molecular pathways involved in glioma biology. IDH1/2: isocitrate 
dehydrogenase 1/2. MDM2/4: mdm2/4 p53 binding protein homolog . CDKN2A: cyclin-
dependent kinase inhibitor 2A. TP53: tumor protein p53. CDKN2A/B/C: cyclin-dependent kinase 
inhibitor 2A/B/C. RB1: retinoblastoma 1. CDK4/6: cyclin-dependent kinase 4/6. CCND2: cyclin 
D2. PI3K: phosphoinositide-3-kinase. PTEN: phosphatase and tensin homolog. AKT: V-akt 
murine thymoma viral oncogene homolog 1. mTOR: mechanistic target of rapamycin. RAS: rat 
sarcoma viral oncogene homolog. NF1: neurofi bromin 1. RAF: V-raf murine sarcoma viral 
oncogene homolog. MAPK: mitogen-activated protein kinase. PLC: phospholipase C. PKC: 
protein kinase C. EGFR: epidermal growth factor receptor. PDGFRα: platelet-derived growth 
factor receptor α. VEGFR: vascular endothelial growth factor receptor. HGFR: hepatocyte growth 
factor receptor. C-KIT: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog. 
MGMT: O6-methylguanine-DNA methyltransferase. Figure from Ricard et al. [3]. 
 
- 1p/19q loss. This alteration is characteristic of gliomas with an oligodendroglial 
component: it is detected in up to 90% of grade II oligodendrogliomas, in 50-70% 
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of anaplastic oligodendrogliomas, in 30-50% of mixed oligoastrocytomas and 20-
30% of anaplastic oligoastrocytomas. It is recognized as a putative prognostic and 
predictive value for anaplastic lesions as associated to a better prognosis, slower 
progression of disease and better response to treatments [2, 3, 5, 6, 10]. 
- p53 pathway alterations. TP53 tumor suppressor gene is mutated or deleted in 
>50% of astrocytic lesions, both low grade and high grade gliomas. It is reported 
that p53 pathways is altered in about 87% of GBMs. TP53 alterations are reported 
as mutually exclusive with amplifications of MDM2 (10% of primary GBMs) or 
MDM4 (4% of primary GBMs) that lead to inactivation of p53 cascade (Figures 
1.1 and 1.2) [2, 3, 5, 6, 10]. 
- Rb pathway alterations. The retinoblastoma (Rb) pathway is a key regulator of 
cell cycle through G1 checkpoint. Alterations in this pathways are encountered in 
about 78% of GBMs. In particular the inactivation of RB gene is found in about 
25% of high grade astrocytomas. In high grade gliomas functional inactivation of 
RB cascade is also caused by CDK4/6 amplifications or by the deletion of 
CDKN2A gene. This latter is common in primary GBMs (50-70%): two proteins, 
p16/Ink4a and p14/ARF, are encoded by CDKN2A, leading to inactivation of Rb 
and p53 pathways respectively (Figures 1.1 and 1.2) [2, 3, 5, 6, 10]. By now the 
prognostic implication of altered p53 or Rb pathways in gliomas remain marginal 
and not fully understood [10]. 
- RTKs pathway alterations. Activations of growth factor tyrosine kinase 
receptors (RTKs), as EGFR, PDGFR or MET, by mutations or amplifications are 
described in about 70% of primary GBMs and have negative prognostic values. 
Moreover multiple RTKs could be found altered at the same time (especially in 
primary GBMs) preventing the inhibitory effect of the target inactivation of a 
single RTK (e.g. using Erlotinib versus EGFR).  
EGFR results amplified in about 50% of GBMs and generally its amplification is 
associated with the expression of the truncated variant EGFRvIII (a constitutive 
oncogenic form due to the genomic deletion of exons 2-7). These alterations are 
mainly associated with high grade gliomas and represent poor prognostic factors.  
PDGFR amplification/mutation or PDGF overexpression are described both in 
low grade gliomas and in GBMs. Elevated levels of PDGFB are described in 
1 . 1  G l i o m a s :  f r o m  c l a s s i f i c a t i o n  t o  t a r g e t  t r e a t m e n t s | 9 
about the 30% of cases, often in association with EGFR or MET amplifications 
(Figures 1.1 and 1.2) [2, 3, 5, 6, 10]. 
- PI3K-Akt pathway alterations Downstream RTKs, the activation of PI3K 
(phosphoinositide-3-kinase) pathway is associated to a higher tumor grade, 
resistance to apoptosis and poor prognosis in gliomas. In response to PI3K 
activation, several signaling proteins are recruited, like PDK1 and Akt/PKB which 
activate directly or indirectly other significant substrates. For example, Akt 
indirectly activates mTOR (TORC2 complex) which acts promoting cell growth. 
In about 15% of GBMs PIK3CA present a gain-of-function mutation, while in 
about 50% of GBMs PTEN (phosphatase and tensin homologue), a negative 
regulator of PI3K-Akt-mTOR pathway, is inactivated by mutations or deletions 
(LOH chromosome 10). In other cases an overexpression of Akt could be detected 
in GBMs, in association to poor prognosis (Figures 1.1 and 1.2) [2, 3, 5, 6, 10, 
11]. 
- Ras-MAPK signaling alterations. RTKs activate Ras-MAPK cascade: the 
dimerization and cross-phosphorilation of RTKs lead to the formation of binding 
sites for Grb2/SOS complex which turns Ras to the active form. High levels of the 
activated Ras-GTP, which activates MEK/ERK/transcription factors cascade, are 
described in high grade gliomas, suggesting that activated RTKs 
mitogenic/proliferative effects in GBMs are mediated also by Ras-MAPK axis. 
Moreover an inactivation of NF1 (neurofibromin 1), a negative regulator of Ras-
MAPK cascade, is reported in about 18% of GBM cases. MAPK cascade 
activation is associated with increased resistance to radiotherapy (Figures 1.1 and 
1.2) [2, 3, 5, 6, 10]. 
- MGMT promoter methylation. O6-methylguanine-DNA methyltransferase, a 
DNA repair enzyme, is epigenetically silenced in 40% of primary GBMs and in 
about 70% of secondary GBMs. This methylation status is also observed in 
anaplastic gliomas (50-80% of cases). MGMT promoter methylation is an 
important prognostic factors because is directly linked to chemotherapy response 
to temozolomide treatment. It is associated with improved outcome in patients 
affected by anaplastic astocytomas and oligoastrocytomas treated with 
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temozolomide, while in anaplastic oligodendroglioma is a prognostic but not 
predictive factor (Figure 1.1) [10]. 
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Figure 1.2 (previuos page). Molecular classification of gliomas. Figure obtained and modified 
from Brennan et al. [6]. On the left the known alterations involved in glioblastoma (GBM) de novo 
pathogenesis. Following Brennan et al. color scheme [6], red boxes indicate activating mutations 
and/or amplifications; green boxes represent silencing mutations and/or gene deletions. Darker 
colors represent a higher prevalence: EGFR alteration is found in approximately 50% of GBM, 
CDKN2A deletion in 50%-70%. Primary GBMs are further subclassified depending on 
transcriptomal patterns: Mesenchymal signature associated with loss of NF1 and p53 mutations; 
Classical characterized by EGFR amplification and loss of PTEN and CDKN2A; Proneural 
signature associated with PDGFR activation, IDH mutation, and amplification of CDK4 and Met. 
This latter one is the only associated also to secondary lesions. The fourth transcriptomal subclass, 
Neural, is not associated with a particular genotype and is not shown.  
On the right, secondary lesions cascades are represented. Gliomas with oligodendroglial 
component are mainly characterized by 1p/19q loss and IDH mutations, while astrocytomas by 
TP53 inactivations. As indicated in the scheme and further explained in the text, the accumulation 
of molecular alterations lead to the secondary GBMs.  
 
1.1 .4  Further  gl ioblas tom a character iza t ion  
In addition to previous described features, Verhaak et al. [7] suggested a further 
classification of GBMs in four transcriptional subclasses according to 
transcriptional data: proneural, mesenchymal, classical and neural. The classical 
form seems to be associated with EGFR amplification, p16 deletion and PTEN 
loss. Mesenchymal subclass is linked to NF1, p53 and CDKN2A alterations. 
Proneural GBMs, with an apparent prognostic advantage in comparison to the 
other subtypes and the only associated to secondary lesions, reported PDGFR, 
CDK4/6, MET amplifications in association to IDH1 and PI3K mutations and 
inactivation of p53 pathway (Figure 1.2). The fourth class, neural GBMs, showed 
a different transcriptional signature without any particular alteration [6, 7]. 
In addition to the previous discussed GBMs markers, other peculiar GBMs 
molecular alterations had been investigated. Distinctive features of GBMs in 
comparison to a lower grade glioma are the presence of marked necrosis, 
vascularization, tumor cell invasion and resistance to apoptosis. Previous studied 
focused their attention on these features to identify other putative biomarkers and 
therapeutic strategies.  
Recently the role of the protein Bcl2L12, an inhibitor of mitochondrial apoptosis 
pathway overexpressed in primary GBMs, was studied. The function of this 
12 | 1 .  I n t r o d u c t i o n  
protein is reported to be relevant to the necrotic process: the suppression of 
caspase activity in mitochondrial death signaling redirects the death program from 
apoptosis to necrosis [5, 12, 13].  
The marked microvascular proliferation in primary and secondary GBMs is 
mainly driven by the overexpression of several pro-angiogenic factors in response 
to intratumour hypoxia: matrix metalloprotease (MMP-2), angiopoietin-1, 
phosphoglycerate kinase (PGK), erythropoietin (EPO), and vascular endothelial 
growth factor VEGFA [14].  
At the base of GBM cells invasiveness, several genes play a crucial role, as a 
metalloproteinases family members (e.g. MMP2 and MMP9 correlate with 
invasiveness, proliferation and prognosis in high astrocytomas) or their inhibitor 
proteins (TIMPs). Moreover also urokinase-type plasminogen activator (uPA) and 
αVβ3 integrin complexes are overexpressed in GBMs and they are relevant to 
GBM invasion [5].  
Finally another characteristic feature of GBM is the trend to resist to apoptosis 
mechanisms. In addition to the activation of mitogenic pathways (Ras-MAPK and 
PI3K-Akt cascades) and the negative regulation of cell-death signaling (p53 and 
Rb cascades), other mechanisms to escape cell death are described in GBMs. 
Expression levels of cell death receptor as CD95, TRAIL, TNFR1 may correlate 
with the response of GBMs to death-induced apoptosis and with prognosis in 
consequence. Anti-apoptotic Bcl-2 family proteins (e.g BAK, BAD, BAX, Bcl-
XL) showed a role in gliomagenesis: for example Bcl-XL is reported upregulated 
in association to overexpression of EGFRvIII in GBMs and this situation lead to 
chemotherapy resistance [5]. Moreover Bcl-2 proteins seem to promote glioma 
cells migration and invasion causing upregulating MMP2 and MMP3 and 
downregulating TIMP2 [15]. 
 
1.1 .5  Target  therapies  in  GBMs  
Whenever possible, surgery remains the first approach for GBM patients 
treatment. In second instance, radio- and/or chemo-therapy (for example using 
temozolomide, obtaining the best results in MGMT methylated cases) are handed 
out. Taking into account the previous considerations on specific GBM molecular 
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alterations, many target therapies were tested, but none passed successfully into 
the clinical practice as main therapy [5, 9]. The difficulty to select an efficient 
single target agent and high failure rate of target therapies in GBMs are associated 
to the great variability in GBMs molecular biology. In Table 1.3 and in Figure 1.3 
are summarized the current inhibitors used in GBM clinical trials [5, 16].  
For example, EGFR inhibitors obtained poor results when handed up as single 
agent. In fact, the presence of the truncated form EGFRvIII increases tumor 
susceptibility to EGFR inhibitors only in the case of active PTEN, while the loss 
of PTEN is associated to EGFR target therapy resistance [17]. Generally EGFR 
inhibitors are less effective if PI3K cascade is intact. Other studies indicated that 
the combinations of EGFR/mTOR inhibitors could have more possibilities even in 
PTEN deficient GBMs [18]. Failure of EGFR target therapy could be also 
explained by the frequent concomitant presence of alterations in other RTKs (e.g. 
PDFGR and/or MET) signaling pathways that lead to tumor progression signals, 
activating Ras/MAPK or PI3K cascades, in spite of EGFR inhibition [5, 10]. 
The combination of more inhibiting factors represent a possibility to elude the 
efficacy of a single therapeutic treatment: blocking more targets within the same 
pathway or in different pathways using multiple agents or a single multi-target 
agent, could improve the efficacy of the treatment although could enhance the risk 
of toxic effects [9]. 
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Table 1.3. Examples of GBM target therapies. Main targets and corresponding drugs are 
indicated [5, 16]. 
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Figure 1.3. Site of actions of main current target therapies for GBM treatment. In the figure 
are represented the main alterations involved in glioma biology and the relative specific drugs: 
aberrant oncogenic RTK pathways can be blocked by small molecules and monoclonal antibodies 
and the consequent activation of PI3K-AKT (green) and RAS (pink) oncogenic pathways are often 
targeted intracellularly with small molecule inhibitors. Figure obtained from Bai et al. [16]. 
 
1.1 .6  Gene therapy s t ra tegies  in  GBMs  
In addition to these target treatments other strategies for GBMs management are 
developed. For example, gene therapy approaches have demonstrated therapeutic 
efficacy in glioma xenograft models and had been enrolled in clinical trials [19, 
20]. The main strategies are: 1) suicide gene therapy, 2) oncolytic viral therapy, 3) 
immunomodulatory therapy and 4) nucleic acid therapies using synthetic vectors 
or nanoparticles [19-21]. 
The first approach is based on the activation of prodrug in situ that blocks DNA 
synthesis leading to tumor cell division arrest. GBM cells are generally 
transfected with a viral vector (e.g. herpes simplex virus or adenovirus) which 
carriers the gene encoding the prodrug activating enzyme. The inactive prodrug, 
administered systematically, becomes active only where the activating enzyme is 
16 | 1 .  I n t r o d u c t i o n  
expressed, resulting to specific tumor cell killing. The most studied prodrug is the 
herpes simplex virus-tymidine kinase (HSV-tk) system which activated the 
inactive prodrug ganciclovir (GCV) in toxic metabolite [19, 20]. 
The oncolytic viral strategy takes advantage of replication-competent viral 
infection which leads to selective tumor cell lysis, with or without gene transfer. 
Oncolytic herpes simplex virus, conditionally replicating adenovirus and 
poliovirus are used in antiglioma oncolyitic virus systems [19, 20]. 
Immunomodulatory gene therapies induce an immune response versus tumor 
cells: it is obtained through the in situ expression of cytokine genes (e.g. IL-2, IL-
12, IL-4, INF-γ, INF-β) or through the recruitment of immune cells, such as 
dendritic cells, to the tumor [19, 20]. 
The last approach considers the gene therapies based on the use of nanoparticles 
or synthetic vectors as delivery systems. These vehicles can cross the blood brain 
barrier (BBB) remaining less immunogenic if compared with viruses: the tumor 
cells specificity is obtained by conjugation with a driving molecule directed 
against proteins specifically expressed on tumor cells [22]. DNA plasmids or 
DNA/RNA oligonucleotides could be delivered across BBB by targeted-
nanoparticles. As regards oligonucleotide strategies, antisense 
oligodeoxynucleotides (AS-ODNs), small interfering RNAs (siRNAs), 
microRNAs (miRNAs) and nucleic acid aptamers are considered. An example is 
the antisense strategy versus TGF-β2, a system yet in clinical trial [23]. The base 
idea of these strategies is to avoid the expression, and therefore preventing protein 
translation, of target genes involved in tumor progression and survival [19, 20]. 
While antisense oligodeoxynucleotides (AS-ODNs), siRNAs and aptamers 
strategies are thought to inhibit specific targets involved in GBMs biology [24, 
25], microRNAs strategy are subjugate to peculiar microRNAs expression of the 
tumor tissue.  
MicroRNAs are small endogenous RNAs that are expressed in a tissue specific 
manner and that are physiologically involved in regulation of several biological 
processes (see section 1.2). Alterations in microRNAs expression and microRNAs 
roles in cancer development and progression have been deeply investigated. For 
these reasons oligonucleotide therapies approaches, based on microRNAs 
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deliveries, could be focused on silencing or restoration of microRNAs 
respectively up- or downregulated in GBMs [26-28]. 
 
1.2 MicroRNAs: from biogenesis  to their functional 
role in glioblastoma 
 
1.2 .1  MicroRNAs b iogenes is  
MicroRNAs are small non-coding RNAs (19-23 nucleotides) that negatively 
regulate gene expression by degrading or suppressing the protein translations of 
mRNAs targets. MicroRNAs sequences represent the 1-3% of whole human 
genome. They are mainly transcribed by RNA polymerase II, even if some 
microRNAs could be transcribed by RNA pol III: the long, stem-loop primary 
transcript (pri-miRNA) is further processed in ~60-70nt pre-miRNA by nuclear 
Drosha RNase III endonuclease. As represented in Figure 1.4, pre-miRNAs are 
transported into cytoplasm by Ran-GTP and the export receptor Exportin-5 
system: once in the cytoplasm, Dicer RNase III endonuclease, process miRNA 
precursors into mature 19-23nt miRNA duplexes. These duplexes comprise the 
mature miRNA and complementary fragment derived from the opposing arm of 
the pre-miRNA (miRNA*). Only the strand with the less stable hydrogen bonding 
at its 5’-end is selected (mature miRNA), while the complementary miRNA* is 
degraded. Mature miRNA is incorporated into ribonucleoprotein (RNP) 
complexes known as micro-RNPs (miRNPs) or miRNA-induced silencing 
complexes (miRISCs). The major components of miRNPs are proteins of the 
Argonaute (AGO) family: these proteins play a central role in binding the mature 
miRNA and drive it to mRNAs target recognition (Figure 1.4) [29-31]. 
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Figure 1.4. MicroRNAs biogenesis. Figure obtained from Filipowicz et al. [31]. 
 
1.2 .2  MicroRNAs mechanism of  act ion  
MicroRNA-RISC complexes recognize and link miRNA complementary regions 
in 3’-UTR of target mRNAs. According to the grade of homology with the 
mRNAs, microRNAs could act in two ways : a perfect complementarity (mainly 
in plants) leads to mRNA cleavage, while an imperfect complementarity (mainly 
in animals) represses mRNA translation with several known mechanisms (Figure 
1.5B) [29, 30, 32]. In the latter case, only the miRNA “seed region” is strictly 
involved in target recognition and binding to mRNA target: a perfect and 
contiguous base pairing between miRNA nucleotides 2 to 8 and 3’-UTR mRNAs 
is required (Figure 1.5A, shown in red). In addition, an “A” residue in mRNA 
sequence corresponding to the position 1 of the miRNA and an “A/U” 
corresponding to the position 9 (Figure 1.5A, shown in yellow) improve the site 
efficiency, although they do not need a perfect match with miRNA nucleotides.  
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Figure 1.5. MicroRNAs-mRNA binding and post-transcriptional gene repression. A) In 
animal cells, miRNAs bind their mRNAs targets imperfectly. A perfect complementarity is 
requested in correspondence of miRNA nucleotides 2 to 8, “seed’ region“ (shown in dark red and 
green, on miRNA and mRNA sequences respectively). The presence on mRNA of an A residue 
corresponding to position 1 of the miRNA, and an A/U corresponding to position 9 (shown in 
yellow), improve the site efficiency, although they do not need a match with miRNA sequence. A 
good base pairing to residues 13–16 of the miRNA (shown in light red) is important to stabilize 
the miRNA-mRNA binding, mainly when matching in the seed region is suboptimal. B) 
MicroRNAs seem to mediate post-transcriptional repression through 4 main mechanisms. At 
translation initiation steps miRNPs complexes can induce deadenylation and decay of target 
mRNAs (upper left), can repress the cap-recognition stage or can block the 60S subunit 
recruitment (bottom left). mRNAs repressed at the translation-initiation stage are stored/degraded 
in P?bodies. At post-initiation phases of translation, miRNPs complexes lead to proteolytic 
cleavage of nascent peptides (upper-right) or to the block of elongation (bottom right). Figure 
modified from Filipowicz et al. [31]. 
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Mismatches must be present in the central region of the miRNA–mRNA duplex, 
precluding the Argonaute (AGO)-mediated endonucleolytic cleavage of mRNA; 
finally miRNA 3′ end must have a good complementarity to stabilize the miRNA-
mRNA binding, in particular the match with residues 13–16 of the miRNA 
(Figure 1.5A, shown in orange). 
These features lead a single microRNAs to recognize and control thousands of 
mRNA targets, and thus several cellular processes at the same time, and a single 
mRNA could be controlled by several microRNAs [33]. 
Several effects of miRNAs are described on protein expression regulation and in 
Figure 1.5B the main mechanisms of miRNAs action are summarized. At the 
initiation step of translation a miRNP complex could induce deadenylation and 
decay of target mRNAs, prevent the recognition of mRNA 5′-terminal cap by the 
eIF4E or could repress the recruitment of the ribosomal 60S subunit. The mRNAs 
not translated because repressed by miRNAs at initiation step, are first stored, and 
then degraded, in P-bodies. The miRNAs repression on post-initiation steps of 
translation inducing the degradation of the nascent peptide or the arrest of the 
elongation through slowing down or ‘drop-off’ ribosomes [31]. 
 
1.2 .3  MicroRNAs target  predict ion  
Once clarified the mechanisms of miRNAs action, many studies were focused on 
understanding their biological function. Their short length and their ability to bind 
several mRNAs with imperfect complementarity, have led to the necessity of the 
develop of useful predicting bioinformatics tools to find their regulatory targets. 
Available algorithms are based on: 1) imperfect complementarity between 
miRNA seed region and 3’-UTR of mRNA target; 2) evolutionary conservation of 
the miRNA recognition elements; 3) thermo-dynamic stability of the miRNA-
mRNA heteroduplex; 4) mRNA sequence features outside the target site [34]. 
The main available prediction tools for mammalians and their principle 
characteristics are listed and summarized in Table 1.4. It is reported that 
prediction algorithms based on stringent Watson–Crick seed pairing have the 
highest specificity, sensitivity and superior predictive power (e.g. TargetScan, and 
PicTar which have also a high degree of overlap) [34, 35]. It is difficult to define 
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if a tool could be superior to another one and it is a common practice using 
different tools at the same time, considering the intersection of their results [36-
39].  
Moreover, depending on the scope of each research study, the analysis of the only 
experimentally validated targets relative to selected miRNAs could be useful. For 
this goal, other web prediction tools are available: for example miRecords [40], 
miRTarBase [41] and miRWalk [42]. 
MiRecords and miRTarBase include manually curated experimental interactions 
based on literature surveying and the experimental techniques used for the 
validation of each microRNA target are ever shown, while miRWalk is based on 
an automated and extensive text-mining search performed on PubMed database 
[40-43]. Therefore this last database includes more interactions than the other two, 
but often less reliable [40-43] and, even in this case, it is common practice 
consider the results intersection of more than one tool at the same time. 
 
1.2 .4  MicroRNAs and cancer  
Due to their key role in the regulation of gene expression, in the last years 
miRNAs tissue specific presence, quantification and functional analysis had been 
deeply investigated to understand their peculiar involvement in cellular processes. 
It is now established that each tissue shows a characteristic microRNAs 
expression pattern which could be modified in association with a number of 
different diseases including neoplastic transformation [28, 44, 45]. It is now found 
that microRNAs could represent important cancer biomarkers, both because their 
expression patterns are tissue specific and mainly because they play a role in 
important cellular processes involved in the tumorigenesis and progression of 
several cancers, including proliferation, invasion, migration and angiogenesis [28, 
44-46]. Many studies have been conducted to define specific microRNAs 
signatures of tumors in several organs, as for example lung [47], pancreas [48], 
prostate [49], thyroid [50], breast [51], melanoma [52], colon [53] and blood [54]. 
The common aim of these studies was to characterize each cancer for miRNAs 
expression in correlation with tumor initiation, progression to higher stages of 
malignancy or with patient survival. 
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In tumors some microRNAs seem to act as oncogenes, also called “oncomir”: 
they are generally highly expressed in tumor tissues and they target genes with 
tumor suppressor activities leading to their significant downregulation, or indeed 
they regulate other genes involved in cell differentiation. In this manner an 
overexpression of oncogenic miRNAs could be related to uncontrolled 
proliferation, resistance to apoptotic signals, neovascular formation and cell 
invasion and migration [44]. An example of a miRNA that acts as oncomir in 
several cancers is miR-21: its main targets are PTEN, PDCD4 and p53 and TGFβ 
network components [55]. 
On the other hand, several other miRNAs have been found to be weakly expressed 
or absent in tumors compared to normal tissue and they act as tumor suppressors. 
Their main targets are oncogenes and/or genes that control cell differentiation or 
apoptosis, that result overexpressed, with obvious advantages for cancer 
progression [44]. An example of a tumor suppressor miRNA could be miR-34a 
which mainly regulates genes like MYCN, BCL2, SIRT1, CAMTA1, NOTCH1, 
JAG1, CCND1, CDK6 and E2F3 [56]. 
 
1.2 .5  MicroRNAs a nd g l ioblastoma 
In the last years several studies have been performed in attempt to identify a 
specific microRNAs expression pattern of GBM [57-76] and a small subset of 
consistently deregulated miRNAs were further functional characterized for their 
activities and downstream targets possibly involved in this tumor [73, 77-81]. 
Recent works of LeBrun et al. [27] and Mizoguchi et al. [82], for example, had 
tried to summarize the results of many GBM miRNAs profiling studies: 
underlying the techniques adopted, the source of tumor and control samples 
analyzed in each study, they focused their attention on miRNAs found 
consistently deregulated. The main microRNAs profiling studies published on 
GBM are summarized in Table 1.5. It is evident the great variability among the 
different studies, going from the technique used for the number of samples 
analyzed, through the non-neoplastic control enrolled and the number of target 
microRNAs studied and finally to miRNAs expression results [27, 82].  
24 | 1 .  I n t r o d u c t i o n  
Profiling  
study  
Method  miRNAs  
analyzed  
Samples  Upregulated  
miRNAs  
Downregulated 
miRNAs  
Chan et al. 
2005 [57] 
Microarray  180  3 fresh GBMs, 
versus 8 NBs, 6 
GBM cell lines 
versus NBs  
miRNA-21, 138, 347, 
135, 291-5'    
miRNA-198, 188, 202 
 
Ciafrè et al. 
2005 [58] 
Microarray  245  9 fresh GBMs 
versus 9 ANBs  
miRNA-10b, 130a, 
221, 125b-1, 125b-2, 
9-2, 21, 25, 123  
miRNA-128a, 181c, 
181a, 181b 
 
Rao et al.  
2010 [63] 
LNA 
Microarray  
756  26 fresh GBMs, 13 
AAs, 7 NBs  
miRNA-21, 146b-5p, 
155, 16, 193a-3p, 
199a/b-3p, 335, 142-
5p, 34a, 513a-5p, 451 
 
miRNA-126, 22, 143, 
381, 24, 552, 886-5p, 
128, 509-3-5p, 376c, 
886-3p, 219-2-3p 
 
Godlewski et 
al. 2008 [62] 
Microarray  245  Unspecified # fresh 
GBMs versus ANBs  
miRNA-383, 519d, 
21, 516-35p, 26a, 
10b, 486, 451  
miRNA-124a, 137, 
323, 139, 218, 128-2, 
483, 128-1, 299, 511-
1, 190  
 
Zhou et al. 
2010 [65]  
Microarray  435  5 GBM cell lines, 1 
AA cell line, and 1 
NB  
miRNA-137, 23b, 
23a, 222, 221, 106, 
15b, 21    
miRNA-451, 124, 495, 
223, 329, 126, 219, 1, 
330, 342, 323, 127, 
128, 132, 95  
 
Conti et al. 
2009 [60] 
RT-PCR 
assay  
8  10 fresh GBMs, 10 
AAs, 8 LGAs, versus 
4 NBs  
miRNA-21, 221  miRNA-181b 
 
Silber et al. 
2008 [59] 
RT-PCR 
assay  
192  Unspecified # of 
fresh GBMs, AAs 
versus NBs    
miRNA-21, 155, 210 
   
miRNA-101, 128a, 
132, 133a, 133b, 149, 
153, 154*, 185, 29b, 
323, 328, 330 
 
Gal et al.  
2008 [61] 
Microarray  NS  CD133+ (stem) vs. 
CD133- (non-stem) 
cells from 6 GBM 
tissues  
miRNA-451, 486, 
425, 16, 107, 185    
None found 
 
Guan et al. 
2010 [67] 
TaqMan 
array  
365  8 fresh GBMs 
versus 4 AAs  
miRNA-15b, 21, 
135(b), 196a, 196b, 
363  
miRNA-105, 128-2, 
184, 302b, 302d, 367, 
383, 504, 517c, 601 
 
Sasayama et 
al. 2009 [73] 
Microarray  127  
or 188  
3 fresh GBMs 
versus ANB  
miRNA-10b, 21, 92b, 
106b, 183  
miRNA-134, 302c, 
329, 369-3p, 379 
 
Malzkorn et al. 
2009 [71] 
RT-PCR 
assay  
157  4 fresh secondary 
GBMs versus DAs  
miRNA-9, 15a, 16, 
17, 19a, 20a, 21, 25, 
28, 130b, 140, 210  
miRNA-184, 328 
 
Zhang et al. 
2013 [76] 
Microarray  1146  82 fresh GBMs vs 5 
NBs  
miRNA-518b, 566  miRNA-181d, 524-5p, 
1227 
 
Lang et al. 
2012 [69] 
Microarray 
and NGS  
NS  3 GBM stem cell 
lines vs 3 normal 
neural stem cell 
lines  
miRNA-10a, 10b, 140-
5p, 204, 424, 34a, 
193a-5p, 455-5p 
 
miRNA-124, 874 
 
Hua et al. 
2012 [68] 
NGS  875  3 fresh GBMs vs 3 
NBs  
Top 10 upregulated: 
miRNA-10b, 96, 10b*, 
182, 135a*, 21*, 21, 
542-3p, 148a, 92b 
 
Top 10 down-
regulated: miRNA-, 
433, 7-1*, 129*, 628-
5p, 935, 218, 31, 876-
3p, 1258, 132 
 
Slaby et al. 
2010 [64] 
RT-PCR 
assay 
8 22 FFPE-dissected 
GBMs vs 6 NBs 
miRNA-21 miRNA-181b, 181c, 
221, 222, 128a 
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Table 1.5 - continued  
Profiling  
study  
Method  miRNAs  
analyzed  
Samples  Upregulated  
miRNAs  
Downregulated 
miRNAs  
Loftus et al. 
2012 [70] 
Microarray  NS  7 GBM cell lines: 
migrating cells vs 
non migrating cells  
miRNA-99a*, 767-3p, 
202*, 556-3p, 655, 
451, 495, 579, 223, 
381, 329, 769-3p,524-
3p, 93*, 220a, 491-
5p,200c*, 133b, 19b-
1*, 520h, 92b, 657, 
891a, 326, 541* 
 
miRNA-16, 30c, 15b, 
23b, 103, 107, 24, 93, 
15a, 151-5p, 23a, 
30b, 30a, 29a, 455-
3p, 25, 106b, 92a, 
125b, 125a-5p, 222, 
17, 20a, 29c, 26a, 
574-3p, 181b, let-7a, 
let-7f, let-7e, let-7b, 
let-7c, let-7d, let- 7g, 
let-7i 
 
Srinivasan et 
al. 2011 [75] 
Microarray  305  222 GBMs vs 10 
NBs (data from 
TGCA)  
miRNA-20a, 106a. 17-
5p, 148a, 146b, 200b, 
193a 
 
miRNA-221, 222, 31 
 
Skalsky et al. 
2011 [74] 
NGS  NS  6 fresh GBMs vs 3 
NBs  
miRNA-10b*, 10b, 
891a, 93, 196b, 21*, 
320d, 217, 4448, 25, 
660, 21, 320c, 296-
3p, 92b, 10a, 92a, let-
7i*, 148a*
 
miRNA-124, 95, 132, 
139-5p, 7, 543, let-
7d, 323-3p, 128, 598, 
103a, 103b, 139-3p, 
487b, 873, 323b-3p, 
138-1*, 301b, 107, 
411-3p, 124*, 342-3p, 
379*, 212, let-7g, 
153, 181d, 22, 889, 
885-5p, 379, 138, let-
7e, 218, 221, 136, 24, 
4787-3p, 126, 548i, 
382, 1270, 495, 2392, 
1273d, 767-5p, 770-
5p, 504, 490-3p
 
Niyazi et al . 
2011 [72] 
Microarray  >1000  35 FFPE GBMs: 
short term vs long 
term survivors  
miRNA-3163  miRNA-539, 1305, 
1260, let-7a 
 
Dong et al. 
2010 [66] 
Microarray  534  240 GBMs vs 10 
NBs f(data from 
TGCA)  
miRNA-141, 21, 155, 
27a, 93, 23a, 196b, 
629, 96, 106b, 492, 
200b, 205, 449, 25, 
130b, 135b, 422a, 
196a, 15b, 17-3p, 
92, 210, 296, 320, 
362, 200c, 200a, 17-
5p, 500, 106a, 30a-
5p, 15a, let-7i, 130a, 
34c, 450, 532, 92b, 
224, 200a*, 199b, 
20a, 503, 193a, 605, 
373*, 452*, 16, 24, 
34b, 505, 502, 602, 
215, 142-3p, 660, 
590, 610, 367, 18a, 
542-3p, 527, 20b, 
195, 339, 214, 142-
5p, 19b, 422b  
miRNA-129, 218, 
124a, 329, 323, 7, 
628, 139, 137, 491, 
379, 138, 410, 485-
5p, 128a, 128b, 154*, 
495, 769-5p, 582, 
132, 433, 103, 598, 
326, 107, 29b, 338, 
153, 330, 539, 411, 
381, 432, 1, 154, 656, 
383, 95, 299-5p, 127, 
758, 29c, 203, 490, 
342, 136, 377, 517c, 
376a*, 380-3p, 409-
5p, 219, 496, 448, 
369-5p, 149, 340, 
133b, 504, 324-5p, 
487b, 577, 485-3p, 
133a, 488, 592, 409-
3p, 346, 331, 33, 
487a, 382, 369-3p, 
125a, 29a, 221  
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Table 1.5 (previous pages). MicroRNAs profiling studies in glioblastoma. GBM: glioblastoma, 
AA: anaplastic astrocytoma, NB: normal brain, ANB: adjacent normal brain, DA: diffuse 
astrocytoma, NS: not specified, NGS: next generation sequencing, TGCA: The Cancer Genome 
Atlas (TCGA) Datasets, FFPE: Formalin-Fixed, Paraffin-Embedded, Bold: common dysregulated 
miRNAs (in at least 3 reports). 
 
From this comparison, only few miRNAs (upregulated: miR-21, 10b, 221, 16, 
451, 193a, 148a, 92b, 196b, 25, 155, 15b and 210; downregulated: miR-128, 
128a, 323, 124, 218, 132, 107, 221, 222, 181b, 95, 153, 379, 126, 495, 504, 329 
and 330, in bold in Table 1.5) shared the same deregulation pattern in at least 3 
studies reported. Interesting to note that miR-221/222, defined as oncomirs in 
GBM and deeply discussed by several works as important microRNAs in GBM 
pathogenesis [60, 83-87], were found both up- and downregulated in at least 3 
profiling studies (Table 1.5).  
Taking in consideration this summary of some of the most cited miRNAs 
profiling studies (Table 1.5), it is clear that by now an exhaustive microRNAs 
profile of glioblastoma is far to be well defined.  
 
Many other works were focused on a single, or a small subset of microRNAs to 
study their function, genetic regulation and expression in GBM tissues/cell lines. 
These functional studies were been very important to validate possible targets of 
those microRNAs found deregulated in many previous profiling works, clarifying 
their molecular roles in GBM pathogenesis with the aim to identify putative 
prognostic or therapeutic biomarkers [26, 46, 56, 57, 59, 61, 62, 65, 67, 73, 77-81, 
87-100]. For example Karsy et al. [88] and Møller et al. [101] have summarized 
the main miRNAs studied in GBM, reporting their functional targets and their 
putative role in tumorigenesis (Table 1.6).  
Finally, taking into account the previous considerations on molecular alterations 
involved in glioblastoma pathogenesis (see paragraph 1.1.3), Figure 1.6 represents 
few examples of how miRNAs could regulate glioblastoma cell proliferation and 
survival, targeting molecules belonging to the principal oncogenic pathways 
discussed above. 
1 . 2  M i R N A s :  f r o m  b i o g e n e s i s  t o  t h e i r  r o l e  i n  G B M | 27 
28 | 1 .  I n t r o d u c t i o n  
Table 1.6. Dysrewgulated miRNAs and their role in GBM [88]. 
 
 
Figure 1.6. Examples of microRNAs actions on oncogenic pathways involved in GBM. 
Upregulated miRNAs are indicated black, downregulated in gray. The dotted arrow indicates an 
indirect control of miR-21 on p53 pathway [102]. 
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1.2 .6  Exper imenta l  s t ra tegies  for  miRNA express ion  analysi s   
A typical microRNAs expression study starts from the choice of the type of 
sample to analyze, the small or broad subset of miRNAs to investigate and the 
most adequate method to apply. The overview of microRNAs expression studies 
in GBMs is extremely heterogeneous, from the experimental set up to results 
obtained (Table 1.5). 
As regards starting material, the common choice spread between Fresh/Frozen 
tumor tissues [57-60, 62, 63, 67, 68, 71, 73, 76] and glioblastoma cell lines [61, 
65, 69, 70, 77, 79, 81]. As reported in Table 1.5 only two studies have adopted 
formalin fixed and paraffin embedded (FFPE) samples as starting material [64, 
72]. The main pros of fresh tissue or cell lines choices is the large quantity and the 
best quality of extracted RNA. On the other hand, the main cons of using cell 
lines to investigate microRNAs expression is that they could not reflect the real 
biological and physiological conditions of GBM: both because they are 
immortalized and they have undergone to molecular modifications which are not 
specific of the tumor in analysis and moreover for the lack of microenvironment 
influence on several steps of tumor progression. Therefore, the use of cell lines for 
profiling studies could result in not reliable data, mainly if compared to the same 
obtained on tumor tissues, but they remain an important resource for miRNAs 
functional studies in vitro. The main cons of using Fresh/Frozen specimens is the 
difficulty to estimate the total amount of neoplastic cells in the starting tissue. In 
fact, even if a first evaluation of neoplastic cells is usually performed on a snap 
frozen section, miRNA/RNA fractions are extracted from an unchecked piece of 
tumor tissue. In this latter it is not possible to determine if the percentage of tumor 
cells is maintained or how much is the normal cells contamination, due to 
lymphocytes, endothelial or normal glial cells, that could surely influence 
expression data. 
It has been reported that microRNAs are not influenced by degradation due to 
formalin fixation as longer RNAs both for their short length (19-25nt) and 
because they are protected by Argonaute protein complex [103-105]. Previous 
studies, focused on different tissues as liver [106], colon [106], prostate [107, 
108], lymphatic tissue node [109, 110] or breast [111], had shown the possibility 
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to analyze microRNAs expression starting from FFPE samples. Many of them 
have compared microRNAs expression in paired Fresh/Frozen and FFPE 
specimens obtaining good correlation values indicating that FFPE tissues are 
suitable for miRNAs analysis and that the obtained results are similar to those 
obtained starting from Fresh/Frozen samples [106, 108, 109]. Once established 
that the putative main cons of starting from FFPE tissues, that was a possible 
limitation in miRNA/RNA extraction, seems to be overcome, several pros are to 
take in consideration: a large number of cases could be retrieved form anatomic 
pathology archives, neoplastic areas could be dissected ensuring a good 
enrichment in neoplastic cells and the possibility to retrieve normal brain tissue is 
higher than fresh samples.  
The number of miRNAs to analyze is an arbitrary selection and influences the 
choice of the most appropriate method to use. The most common techniques used 
in miRNAs expression profiling studies are: microarray expression analysis, real-
time qPCR and next generation sequencing (Table 1.5). 
Microarray analysis, as next generation sequencing techniques (Genome Analyzer 
- Illumina Inc or Genome Sequencer FLX - 454 Life Science and Roche Applied 
Science), let the investigation of a large number of different microRNAs at the 
same time leading to a wide panorama of microRNAs expression in a selected 
tissue. Furthermore, deep sequencing strategies, analyzing thousands sequences in 
parallel from a given sample, could highlight both miRNAs present in few copies 
and could discover novel miRNAs without the limitation of microarray probe 
selection. These high throughput assays are useful to have a broad overview of the 
presence and regulation of microRNAs. However the subset of interesting 
miRNAs resulted from these preliminary analysis, needs to be validated by 
miRNA-specific approaches like Northern Blotting, in situ hybridization (ISH) or 
real-time qPCR [112]. 
Northern blotting is useful to validate specific miRNAs, but it is laboratory-
intensive, time consuming, poor sensitive and requires a large amounts of starting 
material [112]. 
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In situ hybridization (ISH) is the unique technique which permits simultaneously 
to visualize and localize the presence of a specific miRNA in tissue specimen 
cells, but it is not a quantitative assay [112]. 
Quantitative real-time PCR (qRT-PCR) is considered the gold standard for 
quantification of nucleic acid levels and have been widely applied to miRNA 
investigations: it remains the most used techniques for validating microarray/NGS 
results and furthermore it is also used to study miRNAs expression profiles 
analyzing a selected pattern of miRNAs (Table 1.5). It is efficiency, relatively low 
cost, it could start also from low quantity of starting material, and both high and 
low abundance miRNAs can be detected [112]. 
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2.1 PERNO project   
 
The PERNO project (Progetto Emiliano-Romagnolo di Neuro-Oncologia, 
www.perno.it) was launched in 2008 and finished at the end of 2012. It involved 
four universities of Emilia Romagna region (University of Bologna, Ferrara, 
Modena Reggio-Emilia and Parma) and all region local health services (Bologna, 
Ferrara, Forlì-Cesena, Modena-Carpi, Parma-Fidenza, Piacenza, Ravenna, 
Reggio-Emilia and Rimini) gave their precious contribute to the project.  
The main purpose of the this project was to collect primary brain tumor samples 
and their relative epidemiologic data, about prevalence, incidence and prognosis. 
Specific research studies were developed within the PERNO project, all of them 
in strict connection with each other and with professional partnership of 
neurologists, neuroradiologists, neurosurgeons, oncologists, radiotherapists, 
pathologists and molecular biologists.  
The main sub-projects were :  
1- Diagnostic and therapeutic courses of glioblastoma patients: its main aim was 
to evaluate health care course and follow up of glioblastoma patients to guarantee 
them a better assistance; 
2.- Diagnostic and prognostic value of Neuro-Imaging in primitive brain tumors: 
its main aim was to set up non-invasive imaging techniques (e.g. TAC) to 
promptly identify the tumor type and stage, and to promptly recognize possible 
recurrences. 
3- Molecular alterations potentially useful for glioblastoma diagnosis and 
treatment: it consisted of several research studies all involved in the identification 
of molecular alterations in glioblastoma patients, useful as potentially biomarkers 
for target therapies or to improve diagnosis and prognosis definition. 
4- Epilepsy in primitive brain tumors: its main aim was to recognize which factors 
are directly related to seizures appearance in glioblastoma patients, and to clarify 
the prognosis for these patients looking for the most adequate therapies.  
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In detail the third part of the PERNO project was further organized in 5 sub-
categories: 
3a- Expression analysis of IGFBP2 and valuation of its levels in patient sera; 
3b- Analysis of mtDNA molecular alterations and their possible involvement in 
tumor development, progression, chemo- and radio- resistance; 
3c- Expression analysis of a subset of microRNAs which could have a functional 
importance in high grade gliomas; 
3d- Polymorphisms analysis of DNA repair genes and their possible involvement 
in chemo- and radio-resistance;  
3e- Role of ubiquitine-proteasome system in the development of primitive brain 
tumors. 
Among them my PhD research program was based on sub-project “3c”. At the 
beginning of the study, we selected 19 microRNAs known to play a role in 
glioblastoma, according to data yet published in literature (Table 2.1). 
The main aim was to perform the expression analysis of this pattern of 
microRNAs in brain tumors collected within the PERNO project, in order to 
define and to evaluate a possible “microRNAs signature” of glioblastoma. This 
microRNAs profile could be helpful to identify biomarkers potentially useful for 
prognosis, diagnosis or target therapy strategies.  
This present study was performed in the molecular laboratory of Anatomic 
Pathology division of the Bellaria Hospital (University of Bologna). This structure 
represented the case collection center for the PERNO Group: all cases retrieved 
from collaborators were collected in our lab, nucleic acid extractions and 
quantifications for DNA, RNA and microRNAs were performed and DNA/RNA 
aliquots or sample tissues were distributed to PERNO partners. 
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miRNA 
Chromosomal 
localization 
Expression level in GBM [Ref.] 
miR-7  9q21.3 DOWN  [59, 74, 79, 100] 
miR-9  1q22 UP  [58, 71, 96] 
miR-9*  1q22 UP  [58, 71, 96] 
miR-10a  17q21.32 UP  [99] 
miR-10b  2q31.1 UP  [58, 59, 62, 91] 
miR-17  13q31.3 UP  [71] 
miR-20a  13q31.3 UP [71] 
miR-21  17q21.31 UP [58, 59, 62, 71] 
miR 26a  3p22.2 UP  [78] 
miR-27a  19p13.13 UP  [78, 90] 
miR 31  9p21.3 DOWN  [59] 
miR-34a  1p36.22 DOWN  [80, 94] 
miR-101  1p31.3 DOWN  [59, 81] 
miR-137  1p21.3 DOWN  [59, 62] 
miR-182  7q32.2 UP  [78, 113] 
miR-221  Xp11.3 UP  [58, 60, 95, 114] 
miR-222  Xp11.3 UP  [114] 
miR-330  19q13.32 DOWN  [59] 
miR-519d  19q13.42 UP  [62] 
Table 2.1. MicroRNAs chosen for this project. Their chromosomal localization and their 
regulation in GBM is indicated 
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3.1 Ethic Statement 
 
The study was approved by Ethic Committee of Azienda Sanitaria Locale di 
Bologna (number of study 08075, protocol number 139/CE of 5th February 2009, 
Bologna, Italy). All patients signed a written consent for molecular analysis and 
for anonymous data publication for scientific studies and all information regarding 
the human material used in this study was managed using anonymous numerical 
codes. 
 
3.2 Selection of cases 
 
3.2 .1  Glioblas toma group 
Fifty cases of glioblastoma were retrieved at Bellaria (institute of Anatomic 
Pathology, Bologna, Italy) and Bufalini (institute of Anatomic Pathology, Cesena, 
Italy) Hospitals, within PERNO (Progetto Emiliano-Romagnolo di Neuro-
Oncologia) project. All specimens were primary GBMs and patients had not 
undergone neoadjuvant therapy before surgery. Patients were 27 males and 23 
females, aged 41 to 78 years (mean 61.9 yrs). All 50 samples were diagnosed as 
GBM according the 2007 WHO criteria [4]. 
The specimens were collected within one hour after surgery and immediately a 
snap-frozen section was performed. A pathologist evaluated snap-frozen sections 
for each case in order to verify if the tissue was representative of a ‘‘high-grade 
glioma’’. Each sample was divided into three specimens: 1) one fresh specimen 
was incubated in RNA later solution (Applied Biosystem, Austin, TX, U.S.A.) for 
1 hour at room temperature and stored at -80°C after quick-frozen in liquid 
nitrogen (Fresh/Frozen tissues); 2) one fresh specimen followed an alternative 
procedure through under-vacuum treatment in plastic bags; 3) a third fresh 
specimen was directly stored at -80°C after quick-frozen in liquid nitrogen. The 
remaining tissues were routinely processed, formalin fixed and paraffin embedded 
(FFPE), for routine histological analysis. 
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3.2 .2  Normal  adjacent  the  tumor  group 
Normal adjacent the tumor tissues were retrieved at a distance between 1 and 2 
cm from the margin of 15 primary FFPE GBMs. Patients were 8 males and 7 
females, aged 50 to 75 years (mean 62.7 yrs), all belonging from GBM group 
previously described.  
 
3.2 .3  Epi lep t ic  group  
Fifteen polar temporal cortical FFPE specimens, removed in patients submitted to 
surgery (tailored polar anterior temporal resection along with uncus-
amygdalohippocampectomy) for drug-resistant epilepsy, were randomly selected 
from the archives of the Anatomic Pathology of Bellaria Hospital. Epileptic 
patients were 7 males and 8 females, aged 25 to 52 years (mean 39.7 yrs). All of 
them presented drug-resistant anteromedial temporal lobe epilepsy. 
Histologically, eleven cases showed focal cortical dysplasia while four patients 
had hippocampal sclerosis. None of them were affected by a neoplastic lesion, 
including GBM. The tissue used for microRNAs extraction was taken from the 
temporal lobe cortex. 
 
3.2 .4  Grade I I I  Group  
Fifteen cases of grade III gliomas were collected (2 anaplastic ependymomas, 7 
anaplastic oligodendrogliomas, 3 anaplastic astrocytomas, 3 anaplastic 
oligoastrocytomas). Patients were 10 males and 5 females, aged 30 to 74 years, 
mean 50.1 yrs. All samples were diagnosed according the 2007 WHO criteria [4].  
 
3.2 .5  Grade I I  Group  
Fifteen cases of grade II gliomas were collected (2 ependymomas, 7 
oligodendrogliomas, 1 pleomorphic xanthoastrocytoma, 1 astrocytoma and 4 
neurocytomas). Patients were 11 males and 4 females, aged 21 to 74 years, mean 
42.8 yrs. All samples were diagnosed according the 2007 WHO criteria [4].  
3 . 3  N u c l e i c  a c i d  e x t r a c t i o n s | 43 
3.2 .6  Grade I  Group  
Fifteen cases of grade I gliomas were collected (4 pilocytic astrocytomas and 11 
gangliogliomas). Patients were 6 males and 9 females, aged 2 to 35 years, mean 
20.8 yrs. All samples were diagnosed according the 2007 WHO criteria [4].  
The grade I, II and III brain tumors were all randomly selected from the archives 
of the Anatomic Pathology of Bellaria Hospital. 
 
3.2 .7  Commercia l  re ference  
The FirstChoice® Human Brain Reference RNA was purchased from Ambion 
(Ambion, Austin, TX, U.S.A.). According to the manufacturers’ data sheet, this 
was a pool of RNAs obtained from several normal brain regions of 23 healthy 
donors, 13 males and 10 females, aged 23 to 86 (mean 69.7 yrs). FirstChoice® is 
certified to contain small RNAs, including microRNAs. 
 
3.2 .8  Cel l  l ines  
Cell lines of prostate carcinoma (LNCaP, CRL-1740), breast adenocarcinoma 
(MCF7, HTB-22) and glioblastoma (U-87 MG, HTB14), provided by American 
Type Culture Collection (ATCC, Rockville, MD, USA), were used for evaluating 
efficiency of primers per each miRNA analyzed.  
 
3.3 Nucleic acid  extractions 
 
3.3 .1  DNA extract ion  
Fresh/Frozen samples were processed for DNA extraction using MasterPure™ 
DNA Purification Kit (Epicentre, Madison, WI, U.S.A.), according to 
manufacturer’s protocol. DNA was extracted starting from 20 to 50 mg of tissue 
and quantified using the Qubit fluorometer (Invitrogen, Carlsbad, CA, U.S.A.).  
 
3.3 .2  RNA and microRNAs  extract ions  
Fresh/Frozen specimens and cell lines were processed for microRNAs extraction 
using mirVana miRNA isolation kit (Applied Biosystem, Austin, TX, U.S.A.). 
Briefly, total RNA was extracted and small RNA fraction enriched starting from 
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50 to 80 mg of tissue or 3 millions of cells according to manufacturer’s protocol. 
For fresh tissues we proceeded to microRNAs extraction once a pathologist had 
confirmed the presence of at least the 70% of malignant cells, checking a snap 
frozen section. 
RNAs from FFPE samples were extracted using RecoverAll Total Nucleic Acid 
Isolation kit (Ambion, Austin, TX, U.S.A.), according to manufacturer’s 
instructions. The hematoxylin and eosin (H&E) sections were reviewed by a 
pathologist to select the more informative block. Four 20 µm-thick sections were 
cut, followed by one H&E control slide. The area selected for the analysis was 
marked on the control slide to ensure, whenever possible, greater than 90% 
content of glial cells (normal adjacent the tumor and epileptic specimens) or 
neoplastic cells (glioma samples).  
Then the four 20 µm-thick sections were manually macro-dissected using a blade 
according to area selected on H&E and RNAs extraction was performed according 
to manufacturer’s protocol. 
Quality and quantity of RNAs extracted from both Fresh/Frozen and FFPE-
dissected tissue were evaluated using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany) and the Qubit fluorometer (Invitrogen, 
Carlsbad, CA, U.S.A.). 
 
3.4 MicroRNAs analysis  
 
3.4 .1  Assay  des ign  
Nineteen microRNAs (miR-7, miR-9, miR-9*, miR10a, miR10b, miR-17, miR-
20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, 
miR-221, miR-222, miR-330, miR-519d) were chosen according to their role in 
cancer and previously published data in literature at beginning of the study [58-
60, 62, 71, 74, 77-81, 91, 94-96, 99, 100, 113, 114]. MicroRNA103 and two small 
RNAs (RNU49 and U54) were used as endogenous controls. 
MicroRNAs expression was analyzed with quantitative Real-Time PCR (qRT-
PCR), using specific primers designed to recognize the mature microRNA 
sequences, according to miRBase database (http://microrna.sanger.ac.uk) (Table 
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3.1). Forward primers for qRT-PCR were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/). 
 Due to their short length and the high sequence similarity within microRNA 
families, a reliable and accurate quantification system for microRNA analysis was 
needed. For this reason LNA bases were introduced in each forward primer which 
allowed the design of short, very high specific, primers covering most of the 
mature microRNAs sequences. In fact the LNA methylene bridge (Figure 3.1A), 
causing a conformational change of the duplex, confers more rigidity to the 
structure ensuring a higher bond strength between primer and template sequence: 
once introduced in the positions where specificity and discrimination is needed, 
LNA improves mismatch discriminations. 
Moreover, this conformational change increases the annealing temperature of 
duplex allowing the design of shorter primers. So we have designed each 
microRNA primer with 2 or 3 LNA substitutions (Table 3.1), spaced at least one 
nucleotide, assuring an average melting temperature of 60°C for each primer. To 
ensure a good discrimination between microRNAs different just for a single 
nucleotide (e.g. miR-10a and miR-10b, Table 3.1, Figure 3.1) a LNA nucleotide 
was introduced in correspondence of the discriminating base. 
Universal reverse primer was provided by NCode miRNA first-strand cDNA 
synthesis and qRT-PCR Kit (Invitrogen, Carlsbad, CA, U.S.A.).  
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miRNA Fw Primer Sequence used in this study 
hsa-miR-7 TGGAAGACTAGTGATTTTGTT 
hsa-miR-9 TCTTTGGTTATCTAGCTGTATG 
hsa-miR-9* ATAAAGCTAGATAACCGAAAG 
hsa-miR-10a ACCCTGTAGATCCGAATTTG 
hsa-miR-10b ACCCTGTAGAACCGAATTTG 
hsa-miR-17 CAAAGTGCTTACAGTGCAG 
hsa-miR-20a CAAAGTGCTTATAGTGCAG 
hsa-miR-21 TAGCTTATCAGACTGATGTTG 
hsa-miR 26a CAAGTAATCCAGGATAGGC 
hsa-miR-27a TTCACAGTGGCTAAGTTCC 
hsa-miR 31 AGGCAAGATGCTGGCATA 
hsa-miR-34a TGGCAGTGTCTTAGCTG 
hsa-miR-101 TACAGTACTGTGATAACTGAA 
hsa-miR-137 TTATTGCTTAAGAATACGCGT 
hsa-miR-182 TTTGGCAATGGTAGAACTCAC 
hsa-miR-221 GCTACATTGTCTGCTGGGTT 
hsa-miR-222 GCTACATCTGGCTACTGG 
hsa-miR-330 TCTCTGGGCCTGTGTCTTA 
hsa-miR-519d AAGTGCCTCCCTTTAGAGT 
miRNA normalizers 
RNU49 CTGACGAAGACTACTCCTGT 
U54 GTGATAATTTTATACGCTATTCTGA 
hsa-miR-103 CAGCATTGTACAGGGCTATG 
Table 3.1. Forward primer sequences of analyzed microRNAs. LNA bases are underlined. Fw: 
forward. Hsa: Homo sapiens (human). 
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Figure 3.1. Example of microRNAs forward primers with LNA substitutions. A) LNA and 
DNA bases: the arrow indicated the 2’O-4’C Methylene bridge. B) Forward primers for 
microRNAs 10a and 10b which differ for only nucleotide, that is indicated in red. LNA 
substitutions are underlined. 
 
3.4 .2  Primer  e f f i c iency  
To evaluate the efficiency of each primer the small RNAs fractions of 3 cell lines 
were extracted and pooled together: U87-MG (glioblastoma), MCF7 (breast 
cancer) and LNCaP (prostate cancer). Each primer was tested on several cDNA 
dilutions (1:1, 1:25, 1:50, 1:100) and a standard curve titration for each 
microRNA primer was obtained. We considered a good efficiency in the range 
from 90% to 110%. Moreover a pool of female DNA (Promega, Madison, WI, 
U.S.A.) was used as template to verify that each microRNA primer was not able 
to amplify DNA. 
 
3 .4 .3  MicroRNAs express ion analysi s  in  brain  samples   
Both for Fresh/Frozen and FFPE samples, RNA extracted was retro-transcribed 
using the NCode miRNA Firststrand cDNA synthesis and qRT-PCR Kit protocol 
(Invitrogen, Carlsbad, CA, U.S.A.). Briefly cDNAs were obtained after a 
polyadenylation step and retrotranscriptions were performed using SuperScript III 
RT enzyme and a Universal RT Primer according to manufacturer’s protocol. The 
qRT-PCR mixes were prepared using FastStart Taq Reagents Kit (Roche, 
Mannheim, Germany) and microRNAs expression was evaluated using a AB7000 
machine (Applied Biosystem, Foster City, CA, USA) with the following program: 
2 minutes at 50°C, 4 minutes at 95°C followed by 37 cycles for 30 seconds at 
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95°C, 30 seconds of annealing step at 60°C and 30 seconds at 72°C with 
fluorescence measurement. GelStar stain (Lonza Bioscience, Rockland, ME, 
USA) was used as Real-Time detector. No template control for each microRNA 
was included in the reaction plate. Each microRNA was run twice per each 
sample. Amplicons were run on a 3% agarose gel. FirstChoice®Human Brain 
Reference RNA (Ambion, Austin, TX, U.S.A.), considering that it was a pool of 
RNAs, it was analyzed three times (technical replicates).  
 
3.4 .4 .  Bio informat ics  predic t ion  of  microRNAs targets  
The experimentally validated targets of those microRNAs which resulted 
significantly deregulated in GBM profile, had been identified through several 
online tools: miRecords (http://mirecords.umn.edu/miRecords/) [40], miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw) [41] and miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk)[42]. In detail the last releases of miRecords 
(http://mirecords.umn.edu/miRecords/download.php, updated on November 25th, 
2010) and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/download.php, 
“hsa MTI.xls” file, release 3.5 of November 1st, 2012) were downloaded and only 
microRNAs of interest were selected. While the list of selected microRNAs was 
uploaded on miRWalk “Validated target(gene) of mirna search” section 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/mirnatargetpub.html, 
updated on March 11th, 2011) to obtained the list of experimentally validated 
targets relative to each microRNAs of interest. 
In particular we focused our attention only on those targets identified by all 3 
prediction tools used. To analyze and grouped targets according to their molecular 
functions, biological process involvement and pathways classification, 
PANTHER web tool was used (http://www.pantherdb.org/). 
 
3.5 MGMT methylation analysi s 
 
At least 50 ng of DNA were treated with bisulfite using the EpiTect Bisulfite kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. A 
Methylation Sensitive Real Time qPCR using 3’-locked nucleic acid (LNA) 
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modified primers and beacon probes (MS-qLNAPCR, Table. 3.2) was performed 
[115]. The analysis was performed using FastStart Universal Probe Master with 
ROX (Roche Applied Science, Mannheim, Germany) on the AB7000 machine 
(Applied Biosystem, Foster City, CA, USA) with the following conditions: 95°C 
for 4 minutes, 60°C for 2 minutes, 72°C for 2 minutes, followed by 40 cycles for 
20 seconds at 95°C, 45 seconds at 60°C with fluorescence detection, 30 seconds at 
72°C. 
 
 MGMT Methylated MGMT UNMethylated 
Primer Fw 5’-TTTCGACGTTCGTAGGTTTTCGC-3’ 5’-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3’ 
Beacon  
probe 
5’-FAM-CCGGAGCGTATCGTTTGCGA- 
TTTGGTGAGTGTGCTCCGG-BHQ1-3’ 
5’-FAM-CCGGTGCTGTATTGTTTGTGATT- 
TGGTGAGTGTGCACCGG-BHQ1-3’ 
Primer Rv 5’-GCACTCTTCCGAAAACGAAACG-3’ 5’-AACTCCACACTCTTCCAAAAACAAAACA-3’ 
Table 3.2. Primers and beacon probes for MGMT-MSqLNAPCR: LNA nucleotides are 
underlined; CpG discriminatory LNA nucleotides are in bold.[115] Fw: forward; Rv: reverse. 
 
3.6 IDH1 mutation analysis  
 
We tested all tumor samples for IDH1-R132H mutation using Allele Specific 
Locked Nucleic Acid quantitative PCR (ASLNAqPCR), set up by our group for 
KRAS and BRAF analysis [116]. Briefly 15–50 ng of DNA extracted from FFPE 
samples, were amplified using the FastStart Universal Probe Master with ROX 
(Roche Applied Science, Mannheim, Germany) in separate Real Time reactions 
for each allele specific primer. Using Primer3 software 
(http://frodo.wi.mit.edu/primer3/), we designed allele specific primers to 
recognize the IDH1 wild type sequence or the R132H mutation. Both forward 
primers had been designed with 3’-locked nucleic acid (LNA) substitutions to 
improve mismatch discrimination (Table 3.3). The analysis was performed using 
FastStart Universal Probe Master with ROX (Roche Applied Science, Mannheim, 
Germany) on the AB7000 machine (Applied Biosystem, Foster City, CA, USA) 
with the following program: 2 minutes at 50°C, 4 minutes at 95°C followed by 37 
cycles for 30 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C with 
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fluorescence measurement. GelStar stain (Lonza Bioscience, Rockland, ME, 
USA) was used for signal detection. 
 
 IDH1 WT Allele IDH1 R132H Allele 
Primer Fw 5’-TTGATCCCCATAAGCATGAC - 3’ 5’- GTGGCACGGTCTTCAGAGA -3’ 
Primer Rv 5’- TTGATCCCCATAAGCATGAT - 3’ 5’- GTGGCACGGTCTTCAGAGA -3’ 
Table 3.3. Primers for IDH1- ASLNAqPCR: LNA nucleotides are underlined. WT: wild type; 
Fw: forward; Rv:reverse. 
 
3.7 Statistical  analysis  
 
3 .7 .1  MicroRNAs analys i s   
DataAssist 2.0 Tool (Applied Biosystem, Foster City, CA, USA) was used to 
obtain expression values and fold-changes using the relative quantification and the 
2-ΔΔCt method [117]. The unsupervised hierarchical clustering analysis (Pearson 
Correlation, average linkage) were performed using the same statistical tool. 
GraphPad Prism 5.0 tool was used for correlation analysis between groups 
applying Spearman correlation test or Wilcoxon paired test for Fresh/Frozen and 
FFPE-dissected sample pairs analysis. For comparing the expression levels of 
each miRNA between different groups, Kruskal-Wallis and Mann-Whitney tests 
were used. Gaussian distribution was evaluated by Shapiro-Wilk Test. In 
microRNAs analysis in general we adopted a fold change cut-off of twofold: we 
considered as downregulated a microRNA with a ratio <-2.0, while a microRNA 
with a ratio > 2.0 was considered as upregulated. Level of significance was 
p<0.05 for all the statistical analysis. 
 
3.7 .2  MicroRNAs target  analys i s   
A Statistical overrepresentation test [118] was performed using PANTHER web 
tool (http://www.pantherdb.org/tools/uploadFiles.jsp). The target genes list was 
compared to a reference list to statistically determine over- or under- 
representation of PANTHER classification categories. This binomial statistical 
test was applied to analyze PANTHER molecular functions, biological processes 
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and PANTHER pathway classifications. P-values were calculated with Bonferroni 
correction and a p-value cutoff of 0.05 was considered to estimate if a particular 
PANTHER category was over- or under- represented in a significant statistical 
manner than would be expected by chance (indicated by the Expected Values). 
 
3.7 .3  MGMT Methyla t ion  analysi s  and  IDH1 mutat ion  analys i s   
The relative methylated or mutant allele copy number was quantified during the 
exponential phase of Real Time qPCR using the ΔΔCT method [117]. 
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Chapter 4: 
Results 
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4.1 Sample col lection and preservation: u nder vacuum 
treatment versus RNA later f ixation  
 
The best protocol was optimized for sample collection and conservation, avoiding 
or minimizing the nucleic acid degradation. 
The fixation in RNA later solution, before freezing in liquid nitrogen, and the 
under vacuum treatment of tissues in plastic bags were performed in parallel.  
All possible times needed for the transport of the specimens from surgical units to 
our lab, were tested. We have compared samples maintained under vacuum for 0-
6-24-48 hours with the same samples quick-frozen in liquid nitrogen after the 
RNA Later incubation, immediately after surgical removal.  
Under vacuum treatment was proved to be not suitable for these purposes because 
some samples were smashed up due to the mechanic stress of vacuum machine 
and, most of all, the RNA quality was not preserved: RNA was more degraded 
after under vacuum treatment than when samples were fixed in RNA later and a 
RNA later fixation after the arrival to our lab did not preserved RNA quality 
(Figure 4.1).  
As shown in Figure 4.1, RNA quality was not preserved after under vacuum 
treatment even at time zero and RNA was totally degraded after 48h. After RNA 
later fixation (even stored for 48h) a quite good quality of RNA was obtained. For 
this reasons, we have chosen and adopted the RNA later protocol for sample 
collection and storage.  
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Figure 4.1. RNA quality analysis through Agilent 2100 Bioanalyzer platform. A) RNA quality 
analysis of samples underwent to under vacuum treatment for 0-6-24-48 hours. The RNA was 
partially degraded even just at time zero and totally degraded after 48 hours. B) A better RNA 
quality was observed analyzing a sample quick-frozen in liquid nitrogen after fixation step with 
RNA Later solution. The BioAnalyzer software showed an electropherogram and gel-like image, 
that represented two peaks related to the subunit 18S and 28S. The area under the curve is 
proportional to RNA concentration of the sample. 
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4.2 Comparison of microRNAs expression between 
Fresh/Frozen and FFPE-dissected GBM specimens  
 
To set up our method for the analysis of microRNAs expression in GBM samples, 
we performed qRT-PCR starting from microRNAs extracted both from 
Fresh/Frozen and FFPE specimens. In this way the feasibility of our technique on 
both type of specimens was tested and possible discrepancies in microRNAs 
expression values between the two sample types were analyzed. We could 
analyzed microRNAs expression of 30 GBM samples pairs (Table 4.1), available 
both as Fresh/Frozen (FF) and FFPE-dissected (FD) specimens. 
For Fresh/Frozen samples a preliminary 4µm-thick snap frozen section was made 
and checked to verify the presence of the tumor. We could not perform 
microRNA extraction starting from snap frozen slides because the necessity of 
several sections should lead to an excessive sample manipulation, increasing the 
risk of RNA degradation. We proceeded with microRNAs extractions starting 
from pieces of tissue of 20-50 mg in weight, notwithstanding we were not able to 
quantify if the percentage of malignant cells, estimated on snap frozen control 
slide, was maintained in the whole sample that we used for analysis. Even if the 
choice of Fresh/Frozen tissue as starting material ensure a good quality of RNA, it 
was not possible to know the real cellular composition of the specimen: in fact 
some non-neoplastic cells (e.g. lymphocytes, neurons, normal glial cells, 
endothelial cells, etc) could be present in the sample used for the analysis and this 
possibility could altered the microRNAs expression results.  
For this reason in parallel microRNAs from FFPE specimens were also extracted 
after macro-dissection of four 20µm-thick slides according to the tumor area 
selected on an haematoxylin and eosin. In this way a good enrichment (>90%) in 
neoplastic cells was ensured avoiding normal cells contaminations. 
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4.2 .1  GBM Fresh/Frozen  and FFPE -dissected  sample  pairs:  
MGMT and IDH1 sta tus  
Out of 30 GBM cases analyzed, 14 (46.7%) resulted methylated for MGMT 
promoter (Table 4.1). All cases resulted to be wild-type for IDH1, supporting the 
evidence of “primary GBM”[119] (Table 4.1). 
 
Case 
N° 
Code Age Sex 
MGMT 
status 
IDH1 
Status 
Case 
N° 
Code Age Sex 
MGMT 
status 
IDH1 
Status 
1 BO0072 51 M UMET WT 16 BO0652 69 M UMET WT 
2 BO0158 70 F MET WT 17 BO0674 75 F MET WT 
3 BO0160 42 F MET WT 18 BO0858 74 F UMET WT 
4 BO0162 68 F UMET WT 19 BO0902 68 F MET WT 
5 BO0337 69 M UMET WT 20 BO0923 56 M MET WT 
6 BO0363 65 F UMET WT 21 BO0956 69 M UMET WT 
7 BO0364 71 F MET WT 22 BO0968 45 M UMET WT 
8 BO0375 65 F UMET WT 23 BO1081 75 F MET WT 
9 BO0386 71 F MET WT 24 BO1238 60 M UMET WT 
10 BO0530 41 F MET WT 25 BO1278 75 M MET WT 
11 BO0556 61 F UMET WT 26 BO1353 50 M UMET WT 
12 BO0558 55 F MET WT 27 BO1378 49 F MET WT 
13 BO0582 70 M UMET WT 28 BO1412 75 M UMET WT 
14 BO0583 60 M UMET WT 29 BO1477 48 M MET WT 
15 BO0584 77 M MET WT 30 BO1487 67 F UMET WT 
Table 4.1. Glioblastoma cases available both as Fresh/Frozen and FFPE-dissected specimens. 
MGMT methylation and IDH1 mutation status are also indicated. MET: methylated; UMET: 
unmethylated; WT: wild type. 
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4.2 .2  Unsupervised  h ierarchical  c lustering  analys i s  
Unsupervised hierarchical clustering analysis, based on the variation of expression 
of each microRNA across the specimens analyzed, showed that the matched 
samples generally did not cluster together (Figure 4.2A). Figure 4.2B shows the 
unsupervised hierarchical clustering analysis of Fresh/Frozen sample normalized 
on five normal brain specimens. The same sample analyzed as FFPE-dissected 
specimens showed a better separation between tumor and normal group (Figure 
4.2C – see Appendix A for higher magnification). 
 
Figure 4.2. Unsupervised hierarchical clustering analysis of 30 Fresh/Frozen and FFPE-
dissected GBM for the 19 microRNAs analyzed. A) Clustering analysis of the 30 paired 
samples, both tumors and normal brain specimens. FFPE-dissected GBM samples are written in 
green, Fresh/Frozen GBM in pink, Fresh/Frozen normal brains in blue and FFPE control samples 
in red. B) Clustering analysis of the 30 Fresh/Frozen GBM samples: GBM group is written in blue 
and normal brain samples in red. C) Clustering analysis of the 30 FFPE GBM samples: GBM 
group is represented in blue and normal brain samples in red. Blue square highlights GBM group 
and red square the control group. N: normal sample; BO-: anonymous code for GBM samples. 
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4.2 .3  Correlat ion  between Fresh/Frozen  and FFPE-dissected  
groups  for  microRNAs express ion analys i s  
According to the Shapiro Test, the distribution for 30 Fresh/Frozen (FF) and 
FFPE-dissected (FD) GBM sample pairs was not normal (p<0.001). As a 
consequence, non-parametric statistical tests were used. 
Good correlation (r=0.7916, p<0.0001) was obtained when expression levels of 
each microRNA between Fresh/Frozen and FFPE-dissected groups were 
compared (Spearman correlation test, Figure 4.3).  
 
 
Figure 4.3. Spearman correlation scatter plot between Fresh/Frozen and FFPE-dissected 
sample groups. FRESH: Fresh/Frozen sample group; FFPE: FFPE-dissected sample group. 
 
Considering each specimens pair, good correlation values were obtained (ranged 
from 0.5123 to 0.9421) between the microRNAs expression levels (Figure 4.4C). 
In particular this comparison showed a good correlation coefficient (r>0.65) in 25 
out of the 30 sample pairs analyzed (Figure 4.4C).  
We further compared microRNAs expression levels of all samples coupled in two 
groups (Fresh/Frozen versus FFPE-dissected) using Wilcoxon paired t-test and 
not significant differences were observed (p=0.1845). Analyzing samples 
comparing each Fresh/Frozen specimen with the corresponding FFPE-dissected 
one, 8 pairs out of 30 showed statistically significant differences (p-value<0.05, 
Table 4.2).  
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Moreover performing an Anova test with Bonferroni correction, significant 
differences between the two groups were observed in the following 4 microRNAs: 
miR-9*, miR-21, miR-221 and miR-222. 
 
 
Figure 4.4. Spearman correlation test analyzing Fresh/Frozen and FFPE-dissected 
sample pairs. A) An example of a good correlation between paired specimens with a 
Spearman correlation value of 0.9416. B) An example of a not good correlation between 
paired specimens with a Spearman correlation value of 0.5123. C) Table showed all 
Spearman correlation values obtained comparing the 30 GBM sample pairs. 
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Case N° Sample p-value Significance Case N° Sample p-value Significance 
1 BO0072 0,1230 ns 16 BO0652 0,4094 Ns 
2 BO0158 0,0382 * 17 BO0674 0,0559 Ns 
3 BO0160 0,0094 ** 18 BO0858 0,5328 Ns 
4 BO0162 0,7022 ns 19 BO0902 0,0007 *** 
5 BO0337 0,0613 ns 20 BO0923 0,6435 Ns 
6 BO0363 0,0421 * 21 BO0956 0,0464 * 
7 BO0364 0,2197 ns 22 BO0968 0,4566 Ns 
8 BO0375 0,6726 ns 23 BO1081 0,9839 Ns 
9 BO0386 0,0018 ** 24 BO1238 0,2197 Ns 
10 BO0530 0,3869 Ns 25 BO1278 0,0119 * 
11 BO0556 0,1313 Ns 26 BO1353 0,6435 Ns 
12 BO0558 0,9839 Ns 27 BO1378 0,7022 Ns 
13 BO0582 0,7323 Ns 28 BO1412 0,9839 Ns 
14 BO0583 0,1650 Ns 29 BO1477 0,0800 Ns 
15 BO0584 0,0313 * 30 BO1487 0,7628 Ns 
Table 4.2. Wilcoxon paired test results for the 30 GBM pairs. Eight samples out of 30 
analyzed showed significant differences considering a p-value cutoff of 0.05. ns: not 
significant difference was observed. *: p<0.05. **: p<0.01. ***: p<0.001. 
 
4.2 .4  Di f ferences  in  microRNAs express ion  between  
Fresh/Frozen  and FFPE-dissected  specimens  
In spite of the good correlation values obtained between Fresh/Frozen and FFPE-
dissected groups, we verified if microRNAs profiles of the two groups were 
comparable or not. 
We first analyzed microRNAs profile of each Fresh/Frozen GBM versus its 
corresponding FFPE-dissected one and then we calculated the median fold-change 
of each microRNA. 
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Considering a twofold fold change cut-off, we observed that 3 microRNAs (miR-
137, miR-20a and miR-21) were differentially expressed in Fresh/Frozen samples 
if compared with FFPE-dissected ones (FF/FD ratio >2.0), while the remnant 
microRNAs did not shown significantly differences in expression values between 
FF and FD samples (Figure 4.5). 
 
 
Figure 4.5. Median microRNAs expression levels of Fresh/Frozen samples compared with 
FFPE-dissected ones. The two bold lines on the graph highlight the fold change cut-off adopted: a 
microRNA was considered upregulated when it showed a FF/FD ratio >2 or downregulated when 
FF/FD ratio <-2. MicroRNAs which resulted differentially expressed in Fresh/Frozen samples in 
comparison with FFPE-dissected ones, are in red. 
 
4 .2 .5  Correlat ion between Fresh/Frozen ,  FFPE-dissected  and 
FFPE-not  di ssected samples  for  microRNAs expression  analys i s   
In the 5 cases showing a Spearman coefficient <0.65 (Figure 4.4C) we 
investigated if the low correlation values could be due to enrichment in neoplastic 
cells in dissected samples.  
We analyzed the microRNAs profiles of these 5 samples starting from not 
dissected FFPE sections. In 1 out of the 5 cases in analysis (Case#4: BO162), the 
H&E revealed that there was not present not-neoplastic tissue adjacent the 
neoplastic area (Table 4.3).  
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Comparing Fresh/Frozen and FFPE-not dissected samples we obtained a good 
Spearman correlation value, which increased up the cut-off of 0.65, in 3 out of 4 
cases analyzed (Table 4.3). 
 
Case N° Code 
R 
(FF vs FD) 
R 
(FF vs FND) 
Composition of 
not-dissected FFPE samples 
    
Neoplastic  
cells (%) 
Not-neoplastic  
cells (%) 
4 BO162 0,51 NP 98 2 
7 BO364 0,63 0,70 50 50 
8 BO375 0,51 0,38 75 25 
10 BO530 0,62 0,81 70 30 
11 BO556 0,63 0,89 40 60 
Table 4.3. Spearman correlation values analyzing Fresh/Frozen, FFPE-dissected and FFPE-
not dissected sample pairs. FF: Fresh/Frozen; FD: FFPE-dissected; FND: FFPE-not dissected; 
NP: Not Performed. 
 
4.3 Non-neoplastic brain references: normal adjacent 
the tumor, epileptic t issues and commercial brain 
RNA
 
Among the several non-neoplastic controls commonly adopted as reference in 
GBM microRNAs analysis, we had the possibility to compare the following three: 
normal area adjacent the tumor (N-Ad); one of the available commercial normal 
brain RNA (Ref), purchased from Ambion; tissue removed in epileptic patients 
(EP). 
One out of 15 N-Ad in analysis did not give sufficient quantity of microRNAs to 
be used in the analysis.  
Shapiro Test reveled that the distribution for N-Ad, Ref and EP groups was not a 
Gaussian (p<0.001). In according to this result, we used non-parametric statistical 
tests. 
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4.3 .1  Correla t ion  among normal  area  adjacent  the  tumor  (N-Ad),  
commercia l  normal  brain  RNA reference  (Ref )  and  ep i lep t ic  
t i s sue  (EP) groups  
We analyzed the expression of 19 miRNAs in all 3 references and all Spearman 
correlation values obtained were above 0.65, with the best correlation between 
Epileptic tissue and the commercial reference groups (Table 4.4). 
 
 N-Ad Ref Ep 
N-Ad / 0.724 0.702 
Ref 0.724 / 0.848 
Ep 0.702 0.848 / 
Table 4.4. Spearman correlation values between three groups (p<0.0001). Ref: Ambion 
commercial reference; Ep: epileptic group; N-Ad: Normal Adjacent group. 
 
Analyzing the median expression values of each microRNA in the three different 
groups, significant differences were observed (comparing the 3 groups together 
with Kruskal Wallis test, p<0.05) in 9 microRNAs: miR-7, miR-9, miR-10a, miR-
10b, miR-26a, miR-27a, miR-31, miR-137, and miR-182 (Table 4.5). 
Moreover considering groups in pairs (Mann-Whitney test), the significant 
differences obtained with Kruskal Wallis test were confirmed and in addition 
statistical significant differences even in microRNA-101 (between N-Ad and Ref) 
and microRNA-519d (between N-Ad and EP) were observed (Figure 4.6 – see 
Appendix B for higher magnification).  
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miRNAs Median Expression Values p-value* 
 Normal Adjacent 
Tumor 
± Median Error 
Ambion Brain 
Reference 
± Median Error 
Epileptic Tissue 
± Median Error 
 
miR-7 1.441 ± 0.336 2.255 ± 1.515 4.517 ± 0.660 p<0.01 
miR-9 15.898± 3.508 45.191 ± 9.489 24.512 ± 3.744 p<0.05 
miR-9* 1.388± 0.876 4.767 ± 1.504 2.118 ± 0.572 NS 
miR-10a 0.422± 0.249 0.706 ± 0.332 0.207 ± 0.116 p<0.05 
miR-10b 0.356± 0.203 0.258 ± 0.193 0.086 ± 0.118 p<0.05 
miR-17 0.031± 0.038 0.059 ± 0.003 0.051 ± 0.015 NS 
miR-20a 0.039± 0.024 0.094 ± 0.001 0.049 ± 0.020 NS 
miR-21 0.910± 0.814 2.473 ± 0.313 0.974 ± 0.668 NS 
miR-26a 2.699± 0.698 17.851 ± 1.429 4.649 ± 0.779 p<0.01 
miR-27a 0.541± 0.166 0.402 ± 0.036 0.201 ± 0.075 p<0.05 
miR-31 0.077± 0.072 0.366 ± 0.091 0.062 ± 0.017 p<0.05 
miR-34a 0.833± 0.512 0.933 ± 0.355 0.759 ± 0.212 NS 
miR-101 0.254± 0.085 0.632 ± 0.053 0.444 ± 0.171 NS 
miR-137 0.316± 0.099 0.663 ± 0.226 1.042 ± 0.298 p<0.01 
miR-182 0.232± 0.131 0.263 ± 0.091 0.093 ± 0.029 p<0.01 
miR-221 3.753± 0.701 2.914 ± 0.999 5.018 ± 0.907 NS 
miR-222 19.427± 9.525 6.466 ± 2.036 10.655 ± 6.789 NS 
miR-330 0.691± 0.217 0.309 ± 0.053 0.371 ± 0.290 NS 
miR-519d 0.644± 0.259 0.742 ± 0.248 0.309 ± 0.119 NS 
Table 4.5. Median expression values obtained in the three different groups. *p-values were 
obtained using Kruskal-Wallis test. 
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Figure 4.6. Differences in microRNAs expression among three non-neoplastic references. 
Scatter plots show microRNAs significantly different among the three groups. * p<0.05, ** p<0.01 
according to Mann-Whitney test. N-Ad: Normal adjacent the tumor; Ref: Ambion Commercial 
reference; EP: epileptic tissue. 
 
4.4 GBM microRNAs profile  
 
Within the PERNO project, up to 50 glioblastoma specimens for molecular 
analysis were collected.  
In the case BO0375 no residual material was available for further analysis. 
 
4.4 .1  Glioblas toma cases:  MGMT and IDH1 s ta tus  
Out of 50 GBM cases analyzed, 22 (44%) resulted methylated for MGMT 
promoter (Table 4.6). All cases resulted to be wild-type for IDH1, supporting the 
evidence of “primary GBM”[119] (Table 4.6). 
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Case 
N° 
Code Age Sex MGMT  
Status 
IDH1  
status 
Case 
N° 
Code Age Sex MGMT  
status 
IDH1  
status 
1 BO0072 51 M UMET WT 26 BO1353 50 M UMET WT 
2 BO0158 70 F MET WT 27 BO1362 50 M MET WT 
3 BO0160 42 F MET WT 28 BO1378 49 F MET WT 
4 BO0162 68 F UMET WT 29 BO1412 75 M UMET WT 
5 BO0337 69 M UMET WT 30 BO1477 48 M MET WT 
6 BO0363 65 F UMET WT 31 BO1487 67 F UMET WT 
7 BO0364 71 F MET WT 32 CE0226 58 M UMET WT 
8 BO0386 71 F MET WT 33 CE0328 64 F UMET WT 
9 BO0487 78 M UMET WT 34 CE0332 51 F UMET WT 
10 BO0530 41 F MET WT 35 CE0478 66 F NA NA 
11 BO0556 61 F UMET WT 36 CE0636 60 F UMET WT 
12 BO0558 55 F MET WT 37 CE0691 41 M MET WT 
13 BO0582 70 M UMET WT 38 CE0667 59 M UMET WT 
14 BO0583 60 M UMET WT 39 CE0693 63 M MET WT 
15 BO0584 77 M MET WT 40 CE1049 53 M MET WT 
16 BO0652 69 M UMET WT 41 CE1158 74 M UMET WT 
17 BO0674 75 F MET WT 42 CE1159 47 F UMET WT 
18 BO0858 74 F UMET WT 43 CE1286 53 M UMET WT 
19 BO0902 68 F MET WT 44 CE1310 63 M UMET WT 
20 BO0923 56 M MET WT 45 FA0571 58 M UMET WT 
21 BO0956 69 M UMET WT 46 FO0559 56 F MET WT 
22 BO0968 45 M UMET WT 47 FO1173 72 F MET WT 
23 BO1081 75 F MET WT 48 RA1209 72 M UMET WT 
24 BO1238 60 M UMET WT 49 RN0565 60 M MET WT 
25 BO1278 75 M MET WT 50 RN1423 73 F MET WT 
Table 4.6. Glioblastoma cases collected by the PERNO project. MGMT methylation and IDH1 
mutation status are also indicated. MET: methylated; UMET: unmethylated; NA:not avaible; WT: 
wild type. 
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4.4 .2  Def in i t ion  of  a  GBM microRNAs prof i le  
Considering the differences in microRNAs expression observed among the three 
non-neoplastic brain references previously analyzed (Results section 4.3), we 
wondered if the choice of one reference could influence GBM microRNAs profile 
definition. For this reason, we analyzed GBM microRNAs expression matching 
the 50 GBM cases on all 3 non-neoplastic references. A cut-off of 2 fold-change 
had been considered to identify microRNAs differentially expressed. As expected, 
the median expression values of the 19 microRNAs in GBM group were different 
according to non-neoplastic reference adopted as control (Table 4.7). In order to 
define a GBM microRNAs profile, a microRNA was considered as dysregulated 
when it showed the same dysregulated status in at least 2 out of the 3 profiles. The 
final GBM profile is shown in Table 4.8. 
MiR-137, miR-31 and miR-7 were downregulated independently by the non-
neoplastic reference chosen (Tables 4.7 and 4.8, Figure 4.8). In addition miR-9, 
miR-26a, miR-101, miR-222 and miR-330 were downregulated in at least two out 
of three profiles obtained (Tables 4.7 and 4.8, Figure 4.8). Interesting all 
microRNAs with a FC< -2 were also downregulated in at least 50% of analyzed 
glioblastomas (Table 4.7). 
Only 3 microRNAs resulted upregulated in at least 2 out of the 3 profiles 
obtained: in particular microRNA-21 was upregulated (FC>2) independently by 
the reference (Tables 4.7 and 4.8, Figure 4.7) while miR-10b and miR-27a were 
upregulated only considering Ambion reference and Epileptic group as controls 
(Tables 4.7 and 4.8, Figure 4.7). As seen before, also in this case all miRNAs with 
a FC> 2 were upregulated in at least 50% of analyzed tumor cases (Table 4.7). 
Four microRNAs (miR-9*, miR-17, miR-20a, miR34a) showed expression levels 
that were within twofold cut-off independently by the non-neoplastic control used 
and were considered not deregulated. MiR-10a, miR-182, miR-221 and miR-519d 
showed a dysregulated status in only 1 profile out of 3 analyzed (considering 
normal adjacent to the tumor as control for miR-519d or Epileptic group for miR-
10a, miR-182 and miR-221) (Table 4.7). For this reason we excluded these 
microRNAs from GBM profile. 
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Status miRNA Non-neoplastic 
reference 
Median fold Change of GBM Group versus 
  Ref* Ep* N-Ad* 
U
p
re
g
u
la
te
d
 miR-10b Ref, Ep 2.537 (33/50) 4.273 (40/50) ND 
miR-21 Ref, Ep, N-Ad 6.506 (44/50) 10.077 (48/50) 6.832 (45/50) 
miR-27a Ref, Ep 2.095 (28/50) 2.237 (31/50) ND 
      
D
o
w
n
re
g
u
la
te
d
 
miR-7 Ref, Ep, N-Ad -23.641 (48/50) -50.633 (48/50) -15.723 (45/50) 
miR-9 Ref, Ep -2.261 (28/50) -2.144 (25/50) ND 
miR-26a Ref, Ep -8.587 (48/50) -2.229 (28/50) ND 
miR-31 Ref, Ep, N-Ad -15.221 (46/50) -2.811 (29/50) -5.417 (38/50) 
miR-101 Ref, Ep -2.551 (35/50) -2.661 (37/50) ND 
miR-137 Ref, Ep, N-Ad -9.074 (49/50) -16.051 (50/50) -5.408 (45/50) 
miR-222 Ep, N-Ad ND -12.474 (48/50) -10.041 (47/50) 
miR-330 Ep, N-Ad ND -5.168 (41/50) -4.187 (41/50) 
Table 4.8. Final GBM microRNAs profile. MicroRNAs up- or downregulated in GBM in at least 
2 profiles obtained with different non-neoplastic references are shown. * Number of GBMs which 
shared the same deregulation status are indicated between brackets. Ref: Ambion commercial 
reference; Ep: epileptic group; N-Ad: Normal Adjacent group; ND: not deregulated.  
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Figure 4.7. Final GBM microRNAs profile considering microRNAs up- or downregulated in 
at least 2 profiles obtained with different non-neoplastic references. The two bold lines on the 
graph highlight the cut-off of 2 fold-change. Reference: Ambion Commercial Reference; 
Epileptic: Epileptic Group; Norm. Ad.: Normal adjacent the tumor group; FC: fold change. 
 
4.4 .3  Correla t ion  between GBM microRNAs prof i les  obta ined 
us ing  the  three  non -neoplas t ic  re ferences  
Spearman correlation test was used to evaluate the correlation between the 3 
GBM microRNAs profiles obtained with the three non-neoplastic references 
(Table 4.9). 
The best correlation value was observed between profiles obtained using Ambion 
commercial reference and Epileptic group as controls (Table 4.9). Moreover these 
two profiles shared the higher number of microRNAs with the same regulation 
status (Table 4.7 and Table 4.8). 
 
 N-Ad Ref Ep 
N-Ad / 0.7596 (11/19) 0.8421 (10/19) 
Ref 0.7596 (11/19) / 0.8970 (14/19) 
Ep 0.8421 (10/19) 0.8970 (14/19) / 
Table 4.9. Spearman correlation values between microRNAs profiles obtained using the 
three different non-neoplastic references (p<0.0001). The number of miRNAs which shared the 
same deregulation status are indicated between brackets. Ref: Ambion commercial reference; Ep: 
epileptic group; N-Ad: Normal Adjacent group. 
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4.4 .4  Comparison  between MGMT methyla ted  and un-methyla ted 
GBM samples  
Unsupervised hierarchical clustering analysis was performed to compare MGMT 
methylated (MET) and un-methylated (UMET) GBM samples, depending on the 
variation of expression of each microRNA across the specimens analyzed. Only 
the 11 microRNAs demonstrated deregulated in GBM profile were considered 
(Figure 4.8 – see Appendix C for higher magnification).  
Figure 4.8 shows the unsupervised hierarchical clustering analysis of MET-GBM 
and UMET-GBM groups normalized on three normal brain specimens (Ambion 
Commercial Reference in Figure 4.8A, Normal adjacent the tumor in Figure 4.8B 
and Epileptic tissues in Figure 4.8C). It was not observed a clear clusterization 
between the two groups as regard the methylation status, independently by the 
reference. This result indicated that there was not a significant correlation between 
methylation status of MGMT promoter and microRNA expression analysis, 
considering this subset of microRNAs. 
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Figure 4.8. Unsupervised hierarchical clustering analysis of MET-GBM and UMET-GBM 
for the 11 selected microRNAs. Clustering analysis of MET-GBM and UM-GBM samples was 
performed using, Ambion Commercial Reference (A), Normal adjacent the tumor (B) and 
Epileptic tissues (C). MET-GBM samples are written in red, UMET-GBM in green, non-
neoplastic control samples in blue. 
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4.5 Putative  targets  analysis  
 
4 .5 .1  Research  o f  va l idated  targets  of  deregula ted  microRNAs  
Considering only the 11 microRNAs (miR-7, miR-9, miR-10b, miR-21, miR-26a, 
miR-27a, miR-31, miR-101, miR-137, miR-222, miR-330) with a significant 
deregulation in GBMs, we decided to investigate their predicted targets. Taking 
into account that the functional analysis of possible mRNA targets of deregulated 
microRNAs was not a purpose of this project, we restricted our analysis to the 
research of their known targets, experimentally validated in previous studies. To 
do this we used online bioinformatics tools like miRecords, miRTarBase and 
miRWalk. We listed and analyzed all targets found and, as expected, we found 
different numbers of targets, some shared by all three tools used.  
In particular considering the 11 microRNAs all together, we found 102 validated 
targets on miRecords and 219 on miRTarBase, reminding that both tools consider 
manually curated experimental interactions based on literature surveying (Figure 
4.9A). On the other hand we found a higher number of targets on miRWalk (710 
targets, Figure 4.9A), which is based on automated text-mining search. Among 
them only 56 were shared by all analysis tools as shown in Figure 4.9A. In Figure 
4.9B are reported targets relative to each microRNA. In Table 4.10 targets found 
through all 3 bioinformatics tools, relative to each microRNA, are shown.  
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Figure 4.9. Validated targets of the microRNAs GBM profile. A) Targets found through 3 
different tools considering 11 selected microRNAs all together. B) Targets found through 3 
different tools considering microRNA individually. Between brackets is indicated the number of 
targets found using each single tool, while inside circles the numbers of shared targets are 
indicated. 
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miRNA Validated targets found through all 3 bioinformatics tools used 
miR-7 EGFR, IRS1, IRS2, PAK1, RAF1, SNCA 
miR-9 BACE1, CDH1, NFKB1, PRDM1, REST 
miR-10b HOXD10, KLF4 
miR-21 APAF1, BMPR2, BTG2, CDC25A, E2F1, HNRNPK, JAG1, LRRFIP1, MARCKS,  
MTAP, NFIB, PDCD4, PTEN, RASA1, RASGRP1, RECK, SOX5, TGFB1, TGFBR2, 
TIMP3, TPM1 
miR-26a EZH2, SMAD1 
miR-27a FOXO1, PHB, Sp3, Sp4 
miR-31 ITGA5, LATS2, PPP2R2A, RDX, RHOA 
miR-101 ATXN1, EZH2, MCLN1 
miR-137 CDK6, NCOA2 
miR-222 CDKN1B, CDKN1C, ESR1, KIT, MMP1, PPP2R2A, PTEN, SOD2 
miR-330 E2F1, VEGFA 
Table 4.10. MicroRNAs targets shared by miRecords, miRTarBase and miRWalk.  
 
4.5 .2  Prel iminary  analys is  o f  microRNAs targets :  pathways  
involvement ,  molecular  funct ion  and b iological  process  
in format ion  
To perform a preliminary analysis of putative pathways controlled and modified 
by these deregulated microRNAs, PANTHER database 
(http://www.pantherdb.org) was used  
In particular the 56 gene targets, reported by all previously used tools (Figure 
4.9A), were further investigated. This list of gene targets was uploaded on 
PANTHER web tool and pathways, molecular function and biological process 
information were downloaded. From the initial gene list of 56 targets, PANTHER 
was unable to map the gene KLF4, for this reason all further analysis were done 
on 55 gene targets list. In Figure 4.10 PANTHER pathways analysis is reported: 
the 55 genes uploaded had been clusterized depending on their pathways 
involvement. From this preliminary analysis these targets seemed to be involved 
for example in Insulin/IGF pathway-MAPKK/MAP kinase cascade, angiogenesis, 
gonadotropin-releasing hormone receptor (GNRHR), Insulin/IGF-PKB and 
interleukin pathways as shown in Figure 4.10. 
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In Figure 4.11 the Molecular Function analysis of 55 microRNAs targets is 
shown: 55 genes were classified in Molecular Function categories depending on 
PANTHER database. The most represented was the Binding Molecular Function 
Category (GO:0005488), in which 35 genes, out of 55 analyzed, were classified. 
Among them for example 19 target genes were classified as members of “Nucleic 
Acid Binding Molecular Function” Class (GO:0003676) (Figure 4.11B). 
 
 
Figure 4.11. PANTHER Molecular Function analysis of 55 microRNAs targets. A) The 
histogram represents the Molecular Function classes in which these 55 genes are classified 
depending on PANTHER database: GO Molecular Function category is indicated in X-axis, the 
number of member genes is reported in Y-axis. B) The detail of Binding Molecular Function class 
(GO:0005488), in which 35 genes out of 55 analyzed are classified depending on PANTHER 
database, is presented: for example 19/35 genes are members of Nucleic Acid Binding Molecular 
Function Class (GO:0003676). GO:-, Gene Ontology number. 
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In Figure 4.12 the Biological Process analysis of 55 microRNAs targets is 
reported: 55 genes were classified in Biological Process categories depending on 
PANTHER database. The most represented was the Cellular Process Category 
(GO:0009987), in which 36 genes, out of 55 analyzed, were classified. Among 
them for example 27 target genes were classified as members of Cell 
Communication Biological Process Class (GO:0007154) (Figure 4.12B).  
 
 
Figure 4.12. PANTHER Biological Process analysis of 55 microRNAs targets. A) The 
histogram represents the Biological Process classes in which these 55 genes are classified 
depending on PANTHER database: GO Biological Process category is indicated in X-axis, the 
number of member genes is reported in Y-axis. B) The detail of Cellular Process class 
(GO:0009987), in which 36 genes out of 55 analyzed are classified depending on PANTHER 
database, is presented: for example 27/36 genes are members of Cell Communication Biological 
Process class (GO:0007154). GO:-, Gene Ontology number. 
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4.5 .3  Sta t is t i cal  overrepresentat ion  tes t  
The PANTHER binomial statistic tool [118] was used to determine if there was a 
significant statistical over- or under- representation of 55 target genes in 
comparison with a reference list (in this case the default Homo Sapiens Whole 
Genome list was selected). The statistical significance was represented by p-
values: a small p-value (p<0.05) indicated that the number of observed genes in 
each category analyzed (pathway, molecular function or biological process for 
example) was not occurred by chance (randomly). We considered a p-value cutoff 
of 0.05. P-values reported in Table 4.11 were obtained using the Bonferroni 
correction for multiple testing. In Table 4.11 pathways, molecular function classes 
and biological processes interested by 55 gene targets were listed: in particular 
only those that had shown significant p-values had been presented and in all cases 
a statically significant over-representation of number of target genes per category 
was observed.  
In detail, in comparison to the expected value, which represented the number of 
genes we would expect in our target genes list for a particular PANTHER 
category based on the reference list, we observed for all significant categories 
more genes in target genes list than expected. So we obtained a significant 
overrepresentation for all categories listed in Table 4.11 and the significant p-
values indicated that these results were non-random and potentially interesting. 
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Table 4.11. PANTHER overrepresentation analysis. 
a Number of genes in the reference list that 
map to this particular PANTHER classification category; b Number of genes in the target genes list 
that map to this particular PANTHER classification category, c Expected value is the number of 
genes that we could expect in target genes list for this PANTHER category based on the reference 
list; d In the last column is indicated the percentage of target genes list which represented each 
category. P-values are determined by binomial statics with Bonferroni correction: a p-value cutoff 
of 0,05 was considered. 
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4.6 MicroRNAs expression analysis  in g l iomas of 
grade I ,  II  and III  
 
4 .6 .1  Grade I ,  I I  and  I I I  g l ioma cases  
Once set up the method for microRNAs analysis on FFPE samples and once the 
GBM microRNAs profile was defined, we thought to evaluate if there were some 
differences in microRNAs expression associated with different grade of 
malignancy. We were able to retrieve 45 cases of brain tumors of grade lower than 
the IV (Table 4.12). 
In particular cases of gliomas of grade I, II and III were randomly selected from 
the archives of the Anatomic Pathology of Bellaria Hospital. 
Fifteen cases per each grade were selected for microRNAs analysis (Table 4.12).  
MicroRNAs fractions were extracted after macro-dissection of four FFPE 20µm-
thick slides following the tumor area selected on a haematoxylin and eosin by a 
pathologist. Each case was analyzed for the same panel of microRNAs described 
before. 
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4.6 .2  MicroRNAs express ion  analysis  o f  grade I ,  I I  and  I I I  
g l ioma cases   
We analyzed all cases, starting from FFPE specimens, for the same microRNAs 
panel using the Ambion Commercial Reference and the Epileptic Group as 
controls (Tables 4.13 and 4.14). 
In detail we focused our attention on the 14 microRNAs that had shown the same 
deregulation status in GBM expression profiles obtained using the commercial 
reference or epileptic tissues as non-neoplastic controls (Tables 4.7 and 4.8). We 
considered only these two GBM profiles because commercial reference and 
Epileptic group were the same references adopted for grade I, II and III brain 
tumor microRNAs analysis (Table 4.13). 
 
miRNA  Grade IV vs 
Ref/EP  
Grade I vs 
Ref/EP  
Grade II vs 
Ref/EP  
Grade III vs 
Ref/EP  
miR7  DOWN  DOWN  DOWN  DOWN  
miR9  DOWN  =  =  =  
miR9* =  =  =  =  
miR10b  UP  DOWN  DOWN/=
 a
  UP  
miR17  =  =  =  =  
miR20a  =  =  =  =  
miR21  UP  UP  =  =/UP
 a
 
miR26a  DOWN  DOWN/=
a
  DOWN/=
 a
  DOWN/=
 a
  
miR27a  UP  UP  =  =  
miR31  DOWN  DOWN/=
 a
  DOWN/=
 a
  DOWN/=
 a
 
miR34a  =  UP  UP  =  
miR101  DOWN  =  =  DOWN  
miR137  DOWN  DOWN  DOWN  DOWN  
miR519d  =  =  DOWN  DOWN  
Table 4.13. MicroRNAs expression profiles obtained versus Ambion Commercial 
Reference/Epileptic Group. We considered a microRNA as deregulated when it reached the 
cutoff of 2 fold change and it showed the same deregulation status in at least the 50% of cases. a 
Cases in which the results obtained using the 2 references were not the same are reported as results 
on Commercial Refrence/results on Epileptic tissues. Ref: Ambion Commercial Reference; EP: 
Epileptic Group; UP: upregulated; DOWN: downregulated; =: not deregulated. 
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Considering these 3 profiles in comparison with the GBM one (grade IV 
previously obtained) (Table 4.8 and Table 4.13), some interesting differences 
were noticed among groups as regard microRNAs expression status. In particular 
we focused the attention on microRNAs which have showed different regulation 
status among the 4 glioma groups, excluding miR-9*, miR-17 and miR-20a 
because they resulted not deregulated in all analyzed profiles (Tables 4.13 and 
4.14). 
 
4.6 .3  Unsupervised h ierarchical  c luster ing  analys i s  of  g l ioma 
groups  
An unsupervised hierarchical clustering analysis, based on the variation of 
expression of those 14 microRNAs (Table 4.13) across the 4 groups of specimens 
analyzed, showed that there was not a clear separation between different grade 
gliomas (Figure 4.13 – see Appendix D for higher magnification), both using 
Ambion Commercial Reference (Figure 4.13A) or Epileptic group (Figure 4.13B) 
as controls. This might suggest that this panel of microRNAs could be not suitable 
for discriminating gliomas depending on the grade of malignancy and this result 
could be probably due to the choice of microRNAs based on their role specifically 
in GBM (grade IV). 
88 | 4 .  R e s u l t s  
 
 
4 . 6  M i R N A s  e x p r e s s i o n  a n a l y s i s  i n  g l i o m a s  o f  g r a d e  I ,  I I  a n d  I I I | 89 
4.6 .4  Dif ferences  in  microRNAs express ion analysi s  among  
grade I ,  I I ,  I I I  e  IV  g l iomas  
Spearman correlation between the 4 tumor groups indicated, that there was the 
best correlation between high grade gliomas, grade IV (GBM) and III (Table 4.15) 
both considering Ambion Commercial Reference and Epileptic tissues as controls. 
 
A vs Ref Grade IV Grade I Grade II Grade III 
 Grade IV / 0,4592 0,3508 0,6215 
 Grade I 0,4592 / 0,3569 0,2848 
 Grade II 0,3508 0,3569 / 0,4320 
 Grade III 0,6215 0,2848 0,4320 / 
 
B vs EP Grade IV Grade I Grade II Grade III 
 Grade IV / 0,4702 0,3138 0,5872 
 Grade I 0,4702 / 0,3186 0,2538 
 Grade II 0,3138 0,3186 / 0,4175 
 Grade III 0,5872 0,2538 0,4175 / 
Table 4.15. Spearman correlation values between microRNAs profiles obtained for the 4 
tumor groups (p<0.0001). A) Spearman correlation performed on profiles obtained using Ambion 
Commercial Reference as control. The best correlation value was obtained between grade III and 
IV gliomas (in bold). B) Spearman correlation performed on profiles obtained using Epileptic 
Group as control. The best correlation value was obtained between grade III and IV gliomas (in 
bold). Ref: Ambion commercial reference; Ep: epileptic group. 
 
A Mann-Whitney test was further performed, comparing microRNAs expression 
levels of GBM profiles with grade I, II or III gliomas profiles. (Figures 4.14 A and 
B - see Appendix E for higher magnification). As showed in Figures 4.14 A and 
B, we considered microRNAs profiles obtained using both Ambion Commercial 
Reference (Figure 4.14A) and Epileptic Group (Figure 4.14B) as controls. This 
analysis let us to understand which microRNAs were statistically different among 
glioma groups, focusing our attention not only on those microRNAs which have 
showed different regulation status among tumor groups but also on those which 
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shared the same deregulation status to investigate possible statistically significant 
differences in expression levels.  
These results obtained performing Mann-Whitney test are showed in Figures 4.14 
A and B and summarized in Table 4.16.  
Two microRNAs (miR-7 and miR-137) were downregulated in all glioma groups 
even if with some significant differences in expression levels as, for example, 
between GBM and grade II for miR-7 or between GBM and grade I for miR-137. 
Using the Commercial Ambion reference, also microRNA-26a was 
downregulated in GBM as well as in all other tumor groups (Tables 4.7 and 4.14 
and Figure 4.14A) with statistically different levels of expression: in grade I 
(p<0.5), grade II (p<0.001) and grade III (p<0.5) (Table 4.16 and Figures 4.14A). 
Considering the profiles obtained using the epileptic reference, miR-26a resulted 
downregulated only in grade IV brain tumors, even if the same significant 
differences with the other 3 groups were manteined (Figure 4.14B). 
The same consideration could be proposed for miR-31 which resulted 
downregulated in all tumor groups, using Ambion reference as control (Tables 4.7 
and 4.14 and Figure 4.14A). In this case we obtained a statistical different level of 
expression between GBM and grade I glioma samples (Table 4.16 and Figures 
4.14A). On the contrary, using Epileptic tissues as non-neoplastic control group 
miRNA-31 was not-deregulated in grade I, grade II and grade III brain neoplasia 
(Table 4.16 and Figures 4.14B). 
Moreover other 3 microRNAs shared the same deregulation status in high grade 
gliomas (grade III and IV): miR-34a was upregulated in low grade gliomas while 
is not deregulated in high grade tumors (Table 4.16 and Figures 4.14 A and B); 
miR-101 was downregulated only in high grade gliomas (Table 4.16 and Figures 
4.14 A and B) and finally miR-10b was upregulated in high grade gliomas (grade 
III and IV) while was significantly downregulated in low grade gliomas (grade I 
and II) (Table 4.16). In particular the last microRNA resulted downregulated in 
grade I (Table 4.16 and Figures 4.14 A and B), while in grade II it was 
downregulated (Table 4.16 and Figure 4.14A) or not deregulated (Table 4.16 and 
Figure 4.14B), depending on the non-neoplastic reference (Ambion or Epileptic 
respectively). 
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Among the remnant 4 microRNAs, miR-9 was downregulated in GBM, but it is 
not deregulated in grade I, grade II and grade III brain neoplasia (Table 4.16 and 
Figures 4.14 A and B).  
MicroRNA-21, upregulated in GBM, showed high level of expression even in 
grade I, but it was not deregulated in grade II (Table 4.16 and Figures 4.14 A and 
B). In grade III miRNA-21 showed overexpression only when compared with 
Epileptic reference (Table 4.16 and Figure 4.14B). 
MicroRNA-27a was upregulated in GBM and in grade I tumors with a not 
statistical different level of expression (Table 4.16 and Figures 4.14 A and B). On 
the contrary it resulted not deregulated in grade II and grade III brain tumors 
(Table 4.16 and Figures 4.14 A and B). 
Finally miR-519d was not deregulated in GBM and in grade I brain neoplasia 
(Table 4.16 and Figures 4.14 A and B). On the contrary it resulted downregulated 
in grade II and grade III brain tumors (Table 4.16 and Figures 4.14 A and B). 
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Figure 4.14A. Differences in miRNAs expression among the 4 tumor groups. The analysis was 
performed using Ambion Commercial Reference as control. Box plots show microRNAs 
significantly different between GBM Group (Grade IV) and each one of the other 3 tumor groups. 
In Y-axis is indicated the microRNA expression level: “Up” and “Down” lines highlight the cut-
off of 2 fold change to consider a microRNA as deregulated. * p<0.05, ** p<0.01, *** p<0.001 
according to Mann-Whitney test. FC: Fold Change.  
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Figure 4.14B. Differences in miRNAs expression among the 4 tumor groups. The analysis was 
performed using Epileptic Group as control. Box plots show microRNAs significantly different 
between GBM Group (Grade IV) and each one of the other 3 tumor groups. In Y-axis is indicated 
the microRNA expression level: “Up” and “Down” lines highlight the cut-off of 2 fold change to 
consider a microRNA as deregulated. * p<0.05, ** p<0.01, *** p<0.001 according to Mann-
Whitney test. FC: Fold Change.  
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miRNA Brain Tumor Grade 
 
IV  I  p
a
 II  P
a
 III  P
a
 
miR7 DOWN DOWN Ns DOWN ** DOWN ns 
miR9 DOWN = Ns = * = ** 
miR10b UP DOWN *** DOWN/=
 b
 *** UP ns 
miR21 UP UP ns = *** =/UP
 b
 *** 
miR26a DOWN DOWN/=
b 
* DOWN/=
 b
 *** DOWN/=
 b
 * 
miR27a UP UP ns = *** = ns 
miR31 DOWN DOWN/=
 b
 * DOWN/=
 b
 ns DOWN/=
 b
 ns 
miR34a = UP * UP ns = ns 
miR101 DOWN = ** = ** DOWN ns 
miR137 DOWN DOWN *** DOWN ns DOWN ns 
miR519d = = ns DOWN * DOWN *** 
Table 4.16. MicroRNAs expression profiles. Ambion Commercial Reference/Epileptic Group 
were used as non-neoplastic controls. a p value is calculated according to Mann Whitney test 
versus grade IV profile. b Cases in which the results obtained using the 2 references were not the 
same are reported as results on Commercial Refrence/results on Epileptic tissues. Ref: Ambion 
Commercial Reference; EP: Epileptic Group; UP: upregulated; DOWN: downregulated; FC: Fold 
Change; =: not deregulated. * p<0.05, ** p<0.01, *** p<0.001.  
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Chapter 5: 
 Discussion 
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This project was conducted within the multicentric PERNO project (Progetto 
Emiliano-Romagnolo di Neuro-Oncologia, www.perno.it). The main aim was to 
collect and classify primary brain tumor samples and their relative epidemiologic 
data, about prevalence, incidence and prognosis. Among several sub-projects 
started within the PERNO one, this study proposed to identify a set of possible 
molecular markers which could be employed to assist prognosis and diagnosis 
evaluation in high grade glioma patients. In detail this work was focused on the 
expression analysis of a subset of microRNAs which could have a functional role 
in high grade gliomas. 
Despite progresses in surgical techniques, radiotherapy, chemotherapy and “target 
therapy”, the prognosis of primary grade IV glioblastoma, the most frequent and 
malignant brain tumor of the adult, remains poor [4, 8, 9]. In the last years, several 
biomarkers had been proposed as potentially useful parameters for prognosis, 
diagnosis or target therapy strategies. Among them, microRNAs could represent 
important molecular markers, because they play a role in important cellular 
processes involved in the tumorigenesis and progression of cancer and also 
because their expression patterns are tissue specific. Several studies have been 
performed in attempt to identify a specific microRNAs expression pattern of 
GBM [57-65] and a small subset of consistently deregulated miRNAs were 
functionally characterized for their activities and downstream targets involved in 
this tumor [73, 77-81]. 
For this study 19 microRNAs (miR-7, miR-9, miR-9*, miR10a, miR10b, miR-17, 
miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, 
miR-182, miR-221, miR-222, miR-330, miR-519d) were selected for their 
putative role in GBM pathogenesis, according to previously published data [58-
60, 62, 71, 74, 77-81, 91, 94-96, 99, 100, 113, 114]. 
The features that could distinguish a microRNAs profiling study from another one 
are mainly three: the technique performed for microRNAs expression analysis, the 
type of starting material and the choice of control samples enrolled in the analysis.  
As shown by previous published studies, microarray analysis [57, 58, 62, 73] and 
real time-qPCR [59, 60] remain the most commonly used techniques adopted for 
miRNAs investigation.  
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Starting from the assumption that this study was focused on the investigation of 
this small subset of selected microRNAs, previously published in GBM profiling 
studies, we decided to set up a real-time qPCR analysis to investigate the 
expression of these microRNAs in our cohort of GBMs. Between the two 
different methods for reverse transcription for real-time qPCR [112], we adopted 
an universal reverse transcription which included a first step where all miRNAs 
were elongated with a poly(A) tail and then reverse transcribed using a universal 
primer. A good specificity and sensitivity was ensured by using specific forward 
primers designed to correspond to the mature sequence of each microRNA. LNA 
substitutions were added in each primer to improve mismatch discriminations. In 
microRNAs different just for a single nucleotide (e.g. miR-10a and miR-10b), a 
LNA substitution was introduced in correspondence of the discriminating base. 
As regard starting material, Fresh/Frozen tissues [58-60, 63, 73], formalin-fixed 
paraffin embedded (FFPE) specimens [64, 72] or glioblastoma cell lines [65, 77, 
79, 81] are commonly chosen for GBM miRNAs profiling studies. Considering 
the pros and cons of different starting materials (discussed in Introduction 
section), the first part of this project was focused on the evaluation of the most 
suitable specimen for the analysis. For this reason, we have compared microRNAs 
expression between paired Fresh/Frozen and FFPE GBM samples.  
In our study, we collected 30 paired GBMs, available both as Fresh/Frozen and 
FFPE specimens. MicroRNAs expression was analyzed in all 60 samples using 
qRT-PCR. Neoplastic cell percentage was evaluated in Fresh/Frozen tissues on a 
snap frozen section. MicroRNAs extraction was performed starting from 50–80 
mg of not morphologically checked tissue. MicroRNAs from FFPE specimens 
were extracted starting from four 20 µm-thick sections according to the selected 
area signed on H&E control slide (FFPE-dissected), ensuring whenever possible 
an enrichment in neoplastic cells >90%, avoiding “normal” cells contaminations. 
The results of comparison between miRNAs profiles of the two groups showed a 
good correlation (r = 0.7916): only 3 microRNAs (miR-137, miR-20a and miR-
21) were differentially expressed in Fresh/Frozen samples if compared with 
FFPE-dissected ones, while the remnant microRNAs did not shown any 
significant statistically differences in expression values. Moreover considering 
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each specimens pair, good correlation values (r > 0.65) were obtained between the 
microRNAs expression levels in 25 out of the 30 sample pairs analyzed.  
The low correlation in the remnant 5 cases could be due to enrichment in 
neoplastic cells in dissected samples in comparison to Fresh/Frozen ones. 
Analyzing the same cases without performing dissection, we obtained in 3 out of 
4 available cases a better correlation value comparing Fresh/Frozen and FFPE-not 
dissected samples. These results suggest that the previous discrepant results could 
be ascribed to the presence of non-neoplastic cells in Fresh/Frozen tissues.  
To the best of our knowledge, this is the first analysis in glioblastoma samples 
that compares microRNAs expression between paired FFPE-dissected samples 
and Fresh/Frozen specimens. As previously published for other tissues, these 
results demonstrate that miRNAs expression analysis is feasible and results are 
comparable starting from FFPE-dissected GBMs as well as from Fresh/Frozen 
ones [120]. Some significant differences in microRNAs expression levels had 
been showed suggesting that the possible presence, in unknown amount, of non-
neoplastic cells in Fresh/Frozen tissues (endothelial, lymphocytes, normal glial 
cells) could influence microRNAs expression results [120].  
Another key point in microRNAs expression analysis is the choice of non-
neoplastic samples to use as reference controls. The difficulty to retrieve normal 
tissues in brain samples let to choose several non-neoplastic resources and the 
most commonly used references samples are normal adjacent the tumor specimens 
[58, 73, 121], normal brain tissues obtained from epileptic patient surgeries [37, 
59, 60, 63], cell lines [65, 77] and commercial pools of RNAs obtained from 
normal brain areas [67, 71]. To investigate if microRNAs profiles could be 
different depending on the non-neoplastic control used, we compared GBM 
microRNAs expression results obtained using three different non-neoplastic 
references, recreating three frequent experimental conditions. We collected 
normal adjacent the tumor specimens (N-Ad), all from the GBM samples group, 
normal brain tissues retrieved from epileptic patient surgeries (Ep) and a 
commercial pool of brain RNAs (FirstChoiceH Human Brain Reference RNA 
from Ambion; Ref). 
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Analyzing these 3 non-neoplastic references for the same panel of 19 microRNAs, 
a good correlation value (r > 0.65) was obtained comparing the three profiles and 
the best correlation was observed between Ambion Commercial Reference and 
Epileptic Group profiles (r = 0.848). Considering the normal adjacent the tumor, a 
lower correlation value was obtained, both in comparison with epileptic tissues (r 
= 0.702) and commercial reference (r = 0.724). This result might be explained by 
possible alterations in normal tissues adjacent the tumor, due to influence of 
surrounding neoplastic cells. Analyzing the median expression values of each 
microRNA in the three references, 9 microRNAs (miR-7, miR-9, miR-10a, miR-
10b, miR-26a, miR-27a, miR-31, miR-137, and miR-182) resulted statistically 
different comparing the three groups together (Kruskal Wallis test, p<0.05). 
Furthermore, considering groups in pairs (Mann-Whitney test, p<0.05), the 
significant differences obtained with Kruskal Wallis test were confirmed and in 
addition statistical significant differences even in microRNA-101 (between N-Ad 
and Ref) and microRNA-519d (between N-Ad and EP) were observed [122]. 
These discrepancies represented an interesting result because confirmed that, 
although there was a good correlation among microRNAs expression profiles, 
several differences in microRNAs expression distinguish a non-neoplastic control 
from another one. These differences among non-neoplastic references could be 
imputable to: 1) the physiological differences in mean age showed by the three 
control groups (for example epilepsy has an earlier onset in comparison to GBM); 
2) a technical fault encountered during the analysis due to the fact that epileptic 
and normal adjacent the tumor samples were analyzed individually and 
microRNAs expression data were unified in statistical analysis (biological 
variability) while the commercial reference was purchased as a pool of RNAs and 
its analysis was repeated three times (technical variability); 3) non-neoplastic 
samples could have real different microRNAs expression levels [122]. 
Our data confirmed that the choice of the reference control in GBM microRNAs 
profiling study represents a crucial starting point. Moreover it is very important to 
compare microRNAs expression results with data obtained using similar 
experimental conditions (e.g. the source of tumor tissues or the reference control 
adopted) [120, 122]. 
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The third part of the project was focused on the definition of a microRNAs profile 
of GBM group. Fifty GBM samples were collected within the PERNO project 
cohort and they were further analyzed for microRNAs expression.  
Considering the previously obtained data, the analysis was performed on FFPE-
dissected samples, to ensure a good enrichment in neoplastic cells, and GBM 
microRNAs profiles were obtained using all the 3 non-neoplastic references, to 
verify if different controls could provide different GBM microRNAs profiles.  
The median expression values of the 19 microRNAs in GBM group were different 
according to non-neoplastic reference adopted as control. Moreover, even in those 
miRNAs that showed the same status, differences in fold change values can be 
observed (e.g. miR-7, miR-137).  
The best correlation value was observed between profiles obtained using Ambion 
commercial reference and Epileptic group as controls. In addition these two 
profiles shared the higher number of microRNAs with the same regulation status 
(14 out of the 19 microRNAs analyzed). 
To define a GBM microRNAs profile, only microRNAs deregulated in at least 2 
out of the 3 profiles obtained (considering a cut-off of ±2 fold-change), were 
considered. Mir-10b, miR-21 and miR-27a resulted upregulated while miR-7, 
miR-9, miR-26a, miR-31, miR-101, miR-137, miR-222 and miR-330 resulted 
downregulated in GBM group. Only 4 miRNAs (miR-21, miR-7, miR-31 and 
miR-137) showed the same deregulation status in GBM, independently by the 
non-neoplastic reference. The others microRNAs not considered for GBM profile 
were excluded because they resulted not deregulated (miR-9*, miR-17, miR-20a, 
miR34a) or they showed a dysregulated (miR-10a, miR-182, miR-221 and miR-
519d) status in only 1 profile out of the 3 analyzed.  
Bearing in mind the small subset of selected microRNAs, we have defined a 
putative GBM microRNAs profile. Moreover differences observed in microRNAs 
expression among the 3 references described above, let to different GBMs 
microRNAs profiles.  
Our microRNAs GBM profile resulted in accordance with profiling data 
previously reported in literature, except for 3 microRNAs (miR-9, miR-26a and 
miR-222). 
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Mir-9 resulted downregulated in our study (in detail resulted downregulated in 
GBMs versus commercial reference and versus epileptic tissues) while was 
reported upregulated in GBM by Ciafrè et al. [58] and Malzkorn et al. [71]: in the 
first study high levels of miR- 9-2 were evaluated through microarray in 5 out of 9 
fresh tumors compared to their corresponding normal adjacent tissues; while in 
the second study the upregulation of miR-9 was determined by stem-loop realtime 
RT–PCR in 4 fresh secondary GBMs in comparison with their corresponding 
primary grade II gliomas. It should be considered that Ciafrè et al. [58] analyzed 
fresh tumor tissues, not FFPE-dissected samples, and that Malzkorn et al. results 
[71] were obtained in secondary GBMs in comparison not with non-neoplastic 
specimens but with primary grade II gliomas.  
Our results showed a downregulation of miR-26a in GBM, both versus 
commercial reference and epileptic tissues, while the same miRNA was 
previously reported upregulated by Godlewski et al. [62] and Huse et al. [78]. 
Both studies used microarray technique to evaluate microRNAs expression, the 
first one in GBM mouse models after implantation of primary human glioma cells 
derived from freshly resected specimens [62], while the second study performed 
the analysis on 3 fresh GBM samples versus 2 normal brain specimens [78]. Also 
in these cases, the studies design presents significant differences if compared with 
our, for example the use of animal model or the analysis on fresh GBM samples. 
Finally miR-222 resulted significantly downregulated in our study both in 
comparison with epileptic and normal adjacent the tumor tissues. Although miR-
221 and miR-222 are encoded in the same genomic cluster on the X chromosome 
(Entrez Gene www.ncbi.nlm.gov), miR-221 resulted downregulated only versus 
epileptic tissues. Conti et al. [60], Ciafrè et al. [58], Quintavalle et al. [97] and 
Gillies et al. [93] reported an upregulation of miR221/222 cluster in GBM: 
Quintavalle et al. study [97] assessed the specific upregulation of miR-222 using 
microarray technique in GBM cell lines in comparison with non-tumorigenic 
T98G cells; the others evaluated only miR-221 levels, considering that miR-222, 
could shared the same regulation [58, 60, 93]. Conti et al. [60] and Gillies et al. 
[93] used real-time PCR technique on fresh GBM tissues in comparison with 
epileptic specimens and on cell lines, respectively; while Ciafrè et al. [58] used 
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microarray on fresh GBM and normal adjacent tissues as explained before. In 
another study instead Slaby et al.[64] found, by stem-loop RT-PCR, miR-221 and 
miR-222 downregulated in FFPE-dissected GBMs (ensuring >90% of tumor cells) 
in comparison to non malignant brain tissues derived from areas surrounding 
arteriovenous malformation (AVM). Authors explained this result as due to the 
choice of normal brain samples: traces of micro-capillaries from around the AVM 
could be present and, considering that endothelial cells generally showed high 
levels of miR-221/222, this could lead to discrepant results with other studies 
[64]. 
Considering that we analyzed 50 GBM FFPE-dissected samples, adopting 
different non-neoplastic references for the analysis and using qRT-PCR with 
specific LNA primers, these discrepant data could be explained by different 
experimental conditions in which those cited results were obtained. 
Even if the functional analysis of possible mRNA targets of deregulated 
microRNAs was not a purpose of this project, a preliminary analysis of putative 
targets controlled by the selected microRNAs was performed. Considering only 
the 11 microRNAs (miR-7, miR-9, miR-10b, miR-21, miR-26a, miR-27a, miR-
31, miR-101, miR-137, miR-222, miR-330) with a significant deregulation in 
GBMs, their experimentally validated targets were investigated using three online 
tools (miRecords, miRTarBase and miRWalk). Fifty-six validated targets, shared 
by all bioinformatics tools, were further analyzed for their molecular functions 
and pathways involvement using PANTHER database. Interleukin signaling, 
insulin/IGF pathway-MAPKK/MAPK cascade, gonadotropin-releasing hormone 
receptor (GNRHR), angiogenesis and Insulin/IGF-PKB pathways resulted 
significantly represented by this list of targets and previous studies have 
demonstrated their decisive role in glioblastoma pathogenesis [11, 14, 123-129]. 
The aim of the last part of this study was to compare microRNAs expression 
between GBM and gliomas of lower grade (grade I, II and III). We evaluated if 
there were some differences in microRNAs expression associated with different 
grade of malignancy. We focused our attention not only on those microRNAs 
which showed different regulation status among tumor groups but also on those 
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with the same deregulation status for investigating statistically significant 
differences in expression levels.  
As reference controls, due to limited amount of normal adjacent the tumor tissues 
in grade I, II and III, we adopted only epileptic tissues and commercial reference. 
For this reason we focused the attention on 14 microRNAs that have shared the 
same deregulation status in GBM group profiles using these two controls. We 
analyzed the expression of these 14 microRNAs in glioma groups of grade I, II 
and III, comparing the results with the GBM profiles obtained using the same 
references.  
An unsupervised hierarchical clustering analysis revealed that there was not a 
clear separation between different grade gliomas depending on microRNAs 
expression, independently by the reference used. This result indicates that this 
panel of microRNAs could be not suitable for discriminating gliomas simply on 
the grade of malignancy and it could be explained by the arbitrary choice of a 
small subset of microRNAs known to have a role specifically in grade IV gliomas.  
Analyzing microRNAs expression profiles of the 4 tumor groups, the best 
correlation value was obtained between high grade glioma profiles (grade III and 
GBM). Only two microRNAs (miR-7 and miR-137) showed the same 
deregulation status among the 4 tumor groups, independently by the non-
neoplastic control used, even if with some significant differences in expression 
levels as, for example, miR-7 between GBM and grade II or miR-137 between 
GBM and grade I. MiR-26a and miR-31 resulted downregulated in GBM as well 
as in all other tumor groups using only Ambion reference as control. Mir-26a 
presented statistically different levels of expression in all grades when compared 
to GBM, while miR-31 expression level was significantly different only in grade I 
gliomas. Considering the profiles obtained using the epileptic reference, both 
microRNAs resulted downregulated only in grade IV brain tumors, even if the 
same significant differences showed in the analysis with the commercial reference 
were maintained.  
Intriguingly 3 microRNAs shared the same deregulation status only in high grade 
gliomas (grade III and IV): miR-34a, stable in high grade tumors, was upregulated 
in low grade gliomas (grade I and II), miR-101 was downregulated only in high 
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grade gliomas and finally miR-10b resulted upregulated in high grade gliomas 
while was significantly downregulated in low grade gliomas. MiR-34a was 
previously reported in GBM as downregulated and previous studies have analyzed 
its possible role in glioblastoma pathogenesis [92, 94, 98]. Oncogenes like c-met, 
Notch1, Notch2, CDK6, PDGFRA and SMAD4, in TGFβ/SMAD pathway, have 
been validated as targets of miR-34a and they in fact resulted overexpressed in 
GBM [92, 94, 98]. Although miR-34a resulted not deregulated in our high grade 
glioma groups, it showed an upregulation in low grade tumors, suggesting a 
possible association between miR-34a loss and GBM pathogenesis. 
MiR-101 resulted to be downregulated, in accordance with previous studies [59, 
81]. In particular we obtained that this miRNA deregulation could be present only 
in association with high grade of malignancy. Smits et al. [81] have previously 
demonstrated one possible role of miR-101 in GBM progression: they obtained 
lower levels of miR-101 in comparison with grade II-III gliomas and they 
reported the association with overexpression of miR-101 target EZH2, which 
influences proliferation, invasion and angiogenesis. 
Finally miR-10b resulted significantly upregulated in high grade gliomas while 
was downregulated in low grade tumor groups. The data about GBM are in line 
with results previously published by other studies [58, 59, 73, 91]. In particular 
the study by Gabriely et al. [91] demonstrated the role of miR-10b in cell 
proliferation and in cell cycle regulation targeting Bim (a pro-apoptotic factor) 
and p16/CDKN2A - p21/CDKN1B, respectively. Sasayama et al. [73] reported 
that miR-10b expression was associated with glioma grade of malignancy and its 
expression was significantly lower in low grade gliomas compared to high grade 
astrocytic tumors. Moreover they demonstrated that levels of invasive factors 
RhoC and urokinase-type plasminogen activator receptor (uPAR) were inversely 
correlated to miR-10b expression, indicating that it might play a key role in 
invasion features of gliomas. All these data suggested that a silencing of miR-10b 
could be an interesting therapeutic strategy for GBM treatment and a study of 
miR-10b expression in primary low grade gliomas and in corresponding 
secondary GBM lesions could be interesting to evaluate a correlation with tumor 
progression. 
106 | 5 .  D i s c u s s i o n  
 
 
C h a p t e r  6 :  C o n c l u s i o n s  | 107 
 
 
 
Chapter 6: 
 Conclusions 
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We investigated the expression of a panel of 19 microRNAs in brain tumors, 
focusing our attention on GBM expression signature.  
The present study leads to the following considerations: 
1) the feasibility to perform microRNAs profiling study starting from FFPE 
specimens brought three main known advantages: a good disposal of archival 
GBM samples, a greater probability to retrieve normal brain samples which are 
very difficult to obtain as fresh tissues and the possibility to verify the real 
percentage of tumor cells of the analyzed sample (limiting possible 
contaminations of non-neoplastic cells); 
2) the comparison of microRNAs expression using different non-neoplastic 
references highlighted that a GBM microRNAs profile could be strictly 
dependent, not only by the source of tissue, but also by the non-neoplastic control 
chosen; 
3) GBM microRNAs profile has showed mir-10b, miR-21 and miR-27a as 
upregulated, while miR-7, miR-9, miR-26a, miR-31, miR-101, miR-137, miR-222 
and miR-330 resulted downregulated; 
4) comparing expression results in GBM group with glioma groups of lower grade 
(grade I, II and III), we found 3 microRNAs with a different regulation status 
between high grade gliomas (grade III and IV) and low grade gliomas (I and II): 
miR-34a, stable in high grade tumors, was upregulated in low grade gliomas; 
miR-101 downregulated only in high grade gliomas and miR-10b upregulated in 
high grade gliomas while was significantly downregulated in low grade gliomas. 
Among these the last microRNA, miR-10b, could be interesting both as 
therapeutic strategy for GBM treatment and for its possible association with tumor 
progression.  
We concluded this project affirming that in GBM microRNAs profiling studies is 
recommend to compare miRNAs expression results with data previously obtained 
in similar experimental conditions, considering the number of cases analyzed, the 
type of selected tissue, the non-neoplastic control chosen and the technique 
adopted for microRNAs expression analysis. 
Bearing in mind these considerations, further investigations about a specific 
signature of microRNAs expression in GBM could be fundamental to discover 
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new specific therapeutic strategies, for example silencing a microRNA selectively 
overexpressed in GBM, and possible correlations with glioma progression (for 
example extending the analysis on low grade primary glioma tumors and on their 
corresponding secondary high grade lesions). 
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Appendix A 
 
Higher magnification of Figure 4.2. Unsupervised hierarchical clustering 
analysis of 30 Fresh/Frozen and FFPE-dissected GBM for the 19 microRNAs 
analyzed. 
A) Unsupervised clustering analysis of the 30 paired samples, both tumors and 
normal brain specimens. FFPE-dissected GBM samples are written in green, 
Fresh/Frozen GBM in pink, Fresh/Frozen normal brain tissues in blue and FFPE 
control samples in red.  
B) Unsupervised clustering analysis of the 30 Fresh/Frozen GBM samples: GBM 
group is written in blue and normal brain samples in red.  
C) Unsupervised clustering analysis of the 30 FFPE GBM samples: GBM group is 
represented in blue and normal brain samples in red. Blue square highlights GBM 
group and red square the control group.  
N: normal sample; BO-: anonymous code for GBM samples. 
114 | A p p e n d i x  
 
A p p e n d i x  A | 115 
 
 
 
 
 
 
  
116 | A p p e n d i x  
 
Appendix B 
 
Higher magnification of Figure 4.6. Differences in microRNAs expression 
among three non-neoplastic references.  
Scatter plots show microRNAs significantly different among the three groups. * 
p<0.05, ** p<0.01 according to Mann-Whitney test. N-Ad: Normal adjacent the 
tumor; Ref: Ambion Commercial reference; EP: epileptic tissue. 
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Appendix C 
 
Higher magnification of Figure 4.8. Unsupervised hierarchical clustering 
analysis of MET-GBM and UMET-GBM for the 11 selected microRNAs.  
A) Unsupervised clustering analysis of MET-GBM and UM-GBM samples was 
performed using, Ambion Commercial Reference as control. 
B) Unsupervised clustering analysis of MET-GBM and UM-GBM samples was 
performed using normal adjacent the tumor group as control. 
C) Unsupervised clustering analysis of MET-GBM and UM-GBM samples was 
performed using epileptic control group.  
MET-GBM samples are written in red, UMET-GBM in green, non-neoplastic 
control samples in blue. 
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Appendix D 
 
Higher magnification of Figure 4.13: Unsupervised hierarchical clustering 
analysis of 4 tumor groups for the 14 microRNAs analyzed.  
A) Unsupervised clustering analysis of the 50 GBMs (in red), 15 Grade I (blue), 
15 Grade II (green) and 15 Grade III (purple), all normalized on Ambion 
Commercial reference run 3 times (indicated in light blue).  
B) Unsupervised clustering analysis of the 50 GBMs (in blue), 15 Grade I (green), 
15 Grade II (purple) and 15 Grade III (light blue), all normalized on Epileptic 
group (15 cases indicated in red).  
GI: Grade I; GII: Grade II; GIII: Grade III; EP: Epileptic samples; BO-: 
anonymous code for GBM samples.  
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Appendix E 
 
Higher magnification of Figure 4.14. Differences in miRNAs expression 
among the 4 tumor groups.  
The analysis was performed using Ambion Commercial Reference (A) or 
Epileptic group (B) as controls. Box plots show microRNAs significantly 
different between GBM Group (Grade IV) and each one of the other 3 tumor 
groups. In Y-axis is indicated the microRNA expression level: “Up” and “Down” 
lines highlight the cut-off of 2 fold change to consider a microRNA as 
deregulated. * p<0.05, ** p<0.01, *** p<0.001 according to Mann-Whitney test. 
FC: Fold Change.  
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Abstract
miRNAs are small molecules involved in gene regulation. Each tissue shows a characteristic miRNAs epression profile that
could be altered during neoplastic transformation. Glioblastoma is the most aggressive brain tumour of the adult with a
high rate of mortality. Recognizing a specific pattern of miRNAs for GBM could provide further boost for target therapy. The
availability of fresh tissue for brain specimens is often limited and for this reason the possibility of starting from formalin
fixed and paraffin embedded tissue (FFPE) could very helpful even in miRNAs expression analysis. We analysed a panel of 19
miRNAs in 30 paired samples starting both from FFPE and Fresh/Frozen material. Our data revealed that there is a good
correlation in results obtained from FFPE in comparison with those obtained analysing miRNAs extracted from Fresh/Frozen
specimen. In the few cases with a not good correlation value we noticed that the discrepancy could be due to dissection
performed in FFPE samples. To the best of our knowledge this is the first paper demonstrating that the results obtained in
miRNAs analysis using Real-Time PCR starting from FFPE specimens of glioblastoma are comparable with those obtained in
Fresh/Frozen samples.
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Introduction
MicroRNAs (or miRNAs) are small (,20–22 nt) non coding
RNAs that modulate gene expression at a post-transcriptional
level. They act by binding the target mRNAs repressing
translation or regulating their degradation. Each miRNA, playing
its role through perfect and nearly perfect complementarity with
its target mRNAs, could regulate the expression of about a
hundred of genes, influencing a large spectrum of physiological
processes as different steps of cellular development, proliferation or
apoptosis regulation [1].
Many of these pathways are altered in human neoplasia; in fact
it has been demonstrated that miRNAs can act both as oncogenes
or oncosuppressors, according to their target mRNAs [2]. In fact,
in several neoplasia it has been observed that physiological
miRNAs profile resulted modified [3–7].
Glioblastoma (GBM) is a highly malignant astrocytic glioma. It
is the most frequent primary brain tumour and the most malignant
neoplasm with astrocytic differentiation and correspond to WHO
grade IV [8]. Histologically it is composed of poorly differentiated
astrocytic tumour cells, with marked nuclear atypia, high mitotic
activity, prominent microvascular proliferation and necrosis.
Neverthless the progress in neurosurgery, chemio- and radiother-
apy, molecular target identification for focused therapy (MGMT),
the clinical history of the disease is usually short (less than one year
in more than 50% of cases) [8,9].
There are several evidences that different miRNAs could be up-
or down-regulated in GBM. MiR-9/9* [10–12], miR-10a [13],
miR10b [12,14–16], miR17 [11], miR20a [11], miR-21
[11,12,14,16,17], miR26 [18], miR27a [18], miR182 [18,19],
miR-221 [12,20–22], miR-222 [22] and miR-519d [16] were
observed to be up-regulated in GBM (Table 1); on the contrary
miR-7 [14,23–25], miR-31 [14], miR34a [26,27], miR-101
[14,28], miR-137 [14,16], miR-330 [14] were recognized as
down-regulated (Table 1). The increasing evidence that miRNAs
are involved in GBM development and progression could lead to
recognise a specific miRNAs profile for this neoplasia.
It has been demonstrated that, differently from mRNA, integrity
of miRNAs is not influenced by fixation in formalin [29], probably
due to their short length and to the complex Argonaute protein-
miRNA [30]. The comparison of miRNAs expression starting
from Fresh/Frozen or FFPE (formalin fixed and paraffin
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embedded) material was performed in culture cells [31] and in
several tissues as prostate [32,33], breast [34–36], kidney
[29,37,38], lymphatic tissue [39,40], tonsils [37], melanocytic nevi
[41], colon carcinoma [38] and in one case of oligodendroglioma
[42]. All these papers have demonstrated that there was a good
correlation in miRNAs expression analysis starting both Fresh/
Frozen and FFPE tissue. None of them, except for Nonn et al.
[32], performed dissection in Fresh/Frozen or FFPE material.
Most of miRNAs expression studies in GBM were performed on
Fresh/Frozen tissue or cell lines. In central nervous system
neoplasia, starting from FFPE tissue could be very useful because
of archival material is readily available and follow-up is often
known.
Aim of this study was to investigate the expression of 19
miRNAs in GBM starting from both Fresh/Frozen and FFPE-
dissected tissues. In these last samples, the dissection allowed to
enrich (.90%) the analysed material of neoplastic cells, limiting
the eventual contamination due to ‘‘normal near the tumour’’
fraction (e.g. lymphocytes, stroma, not neoplastic glial and
neuronal cells). In this way we would to investigate the feasibility
of miRNAs expression analysis starting from FFPE tissues in
GBM, looking for eventually differences between not dissected
Fresh/Frozen samples and FFPE-dissected tissues.
Materials and Methods
Ethic Statement
The study was approved by Ethic Committee of Azienda
Sanitaria Locale di Bologna (number of study 08075, protocol
number 139/CE of 5th February 2009, Bologna, Italy). All patients
signed a written consent for molecular analysis and for anonymous
data publication for scientific studies and all information regarding
the human material used in this study was managed using
anonymous numerical codes.
Selection of Cases
Thirty cases of GBM were selected for miRNAs expression
analysis from cases collected at Bellaria (institute of Anatomia
Patologica, Bologna, Italy) and Bufalini (institute of Anatomia
Patologica, Cesena, Italy) Hospitals, within PERNO (Progetto
Emiliano-Romagnolo di Neuro-Oncologia) project. All specimens
were primary GBM, and patients had not undergone neoadjuvant
therapy before surgery. Patients were 14 males and 16 females,
aged from 42 to 75 years (mean 63.3 ys).
The specimens were collected no longer than 45 minutes after
removal and immediately a snap-frozen section was performed
and the material evaluated by a pathologist in order to verify if the
tissue was represented by a ‘‘high-grade glioma’’.
A sample of tissue was then incubated in RNA later solution
(Applied Biosystem, Austin, TX, U.S.A.) for 1 hour at room
temperature and stored at 280uC after quick-frozen in liquid
nitrogen. The remaining specular tissue was formalin fixed and
paraffin embedded for routine histological diagnosis. All 30
samples were diagnosed as GBM according the 2007 WHO
criteria [8].
Cell lines of prostate carcinoma (LNCaP, CRL-1740), breast
adenocarcinoma (MCF7, HTB-22) and glioblastoma (U-87 MG,
HTB14), provided by American Type Culture Collection (ATCC,
Rockville, MD, USA), were used for evaluating efficiency of
primers per each miRNA analysed.
miRNAs extraction
The ‘‘Fresh/Frozen’’ specimens and cell lines were processed
for miRNAs extraction protocol using mirVana miRNA isolation
Table 1. Name, chromosomal localization and expression
level in GBM according to previously described data of
miRNAs analysed in this study.
miRNA Localization Up/Downregulated in GBM Reference
9/9* 1q22 UP [10–12]
10a 17q21.32 UP [13]
10b 2q31.1 UP [12,14–16]
17 13q31.3 UP [11]
20a 13q31.3 UP [11]
21 17q21.31 UP [11,12,14,16,17]
26 3p22.2 UP [18]
27a 19p13.13 UP [18]
182 7q32.2 UP [18,19]
221 Xp11.3 UP [12,20–22]
222 Xp11.3 UP [22]
519d 19q13.42 UP [16]
7 9q21.3 DOWN [14,23–25]
31 9p21.3 DOWN [14]
34a 1p36.22 DOWN [26,27]
101 1p31.3 DOWN [14,28]
137 1p21.3 DOWN [14,16]
330 19q13.32 DOWN [14]
doi:10.1371/journal.pone.0035596.t001
Table 2. Name, localization and forward primer sequence of
analysed miRNAs.
miRNA Fw Primer Sequence
hsa-miR-7 TGGAAGACTAGTGATTTTGTT
hsa-miR-9 TCTTTGGTTATCTAGCTGTATG
hsa-miR-9* ATAAAGCTAGATAACCGAAAG
hsa-miR-10a ACCCTGTAGATCCGAATTTG
hsa-miR-10b ACCCTGTAGAACCGAATTTG
hsa-miR-17 CAAAGTGCTTACAGTGCAG
hsa-miR-20a TAAAGTGCTTATAGTGCAG
hsa-miR-21 TAGCTTATCAGACTGATGTTG
hsa-miR-26a CAAGTAATCCAGGATAGGC
hsa-miR-27a TTCACAGTGGCTAAGTTCC
hsa-miR-31 AGGCAAGATGCTGGCATA
hsa-miR-34a TGGCAGTGTCTTAGCTG
hsa-miR-101 TACAGTACTGTGATAACTGAA
hsa-miR-137 TTATTGCTTAAGAATACGCGT
hsa-miR-182 TTTGGCAATGGTAGAACTCAC
hsa-miR-221 GCTACATTGTCTGCTGGGTT
hsa-miR-222 GCTACATCTGGCTACTGG
hsa-miR-330 TCTCTGGGCCTGTGTCTTA
hsa-miR-519d AAGTGCCTCCCTTTAGAGT
LNA bases are underlined. Fw: forward. Hsa: Homo sapiens (human).
doi:10.1371/journal.pone.0035596.t002
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kit (Applied Biosystem, Austin, TX, U.S.A.). Briefly, small RNA
fraction was exctracted and enriched starting from 50 to 80 mg of
tissue or 3 millions of cells according to manufacturer’s protocol.
The haematoxylin and eosin (H&E) sections from FFPE
specimens were reviewed by a pathologist (GM) to select the
more informative block. Four 20 mm-thick sections were cut
followed by one H&E control slide. The tumour area selected for
the analysis was marked on the control slide to ensure, whenever
possible, greater than 90% content of neoplastic cells (avoiding
necrosis and lymphocytes). The four 20 mm-thick sections were
manually dissected under microscopic guidance according to area
selected on H&E and incubated in xylene for 3 minutes at 50uC
and, after two rinses with ethanol, miRNAs were extracted using
RecoverAll Total Nucleic Acid Isolation kit (Ambion, Austin, TX,
U.S.A.), according to manufacturer’s instructions.
Quality and quantity of smallRNAs extracted from both Fresh/
Frozen and FFPE-dissected tissue were evaluated using the Agilent
2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany)
and the Qubit fluorometer (Invitrogen, Carlsbad, CA, U.S.A.).
cDNA was obtained after a polyadenylation step and retro-
transcription were performed using SuperScript III RT enzyme
and a Universal RT Primer according to NCode miRNA first-
strand cDNA synthesis and qRT-PCR Kit protocol (Invitrogen,
Carlsbad, CA, U.S.A.).
miRNAs analysis
Nineteen miRNAs (Table 1) were selected for analysis,
according to their role in cancer and data previously published
in literature at beginning of the study [10–12,14,16–
18,20,21,24,25,27]. miR103, RNU49 and U54 were used as
endogenous controls.
Each forward primers used correspond to mature miRNA
sequence according to miRBase database (http://microrna.
sanger.ac.uk) (Table 2). Primers were modified with LNA (Locked
Figure 1. Scatter plot showing Spearman correlation between Fresh/Frozen and FFPE-dissected groups.
doi:10.1371/journal.pone.0035596.g001
Figure 2. Median fold-change calculated per each miRNA between 30 paired Fresh/Frozen and FFPE samples. The y-axis represents the
fold-change value.
doi:10.1371/journal.pone.0035596.g002
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Nucleic Acid) substitutions for increasing specificity and discrim-
inating between miRNAs with a single base different nucleotide
sequences (e.g. miR-10a and miR-10b, Table 2). Universal reverse
primer was provided by NCode miRNA first-strand cDNA
synthesis and qRT-PCR Kit (Invitrogen, Carlsbad, CA, U.S.A.).
Efficiency of each primer was tested by Real-Time PCR using
serial dilutions (1:1, 1:25, 1:50, 1:100) of a pool of RNA extracted
by following cell lines: U-87 MG, MCF7 and LNCaP. A run of
Real-Time PCR using as template a pool of female DNA
(Promega, Madison, WI, U.S.A.) was performed to confirm that
miRNAs primers were not able to amplify DNA.
miRNAs expression was evaluated using a AB7000 machine
(Applied Biosystem, Foster City, CA, USA) and FastStart Taq
Reagents Kit (Roche, Mannheim, Germany), with the following
program: 2 minutes at 50uC, 4 minutes at 95uC and 37 cycles with
annealing at 60uC for 30 seconds. GelStar stain (Lonza Biosci-
ence, Rockland, ME, USA) was used as Real-Time detector. No
template control for each miRNA was included in the reaction
plate. All the reactions were performed in duplicate and amplicons
run on a 3% agarose gel.
Statistical analysis
Expression values and fold-change were obtained by relative
quantification and 22DDCt method [43], using DataAssist 2.0 Tool
(Applied Biosystem, Foster City, CA, USA). Statistical analysis of
miRNAs expression was performed using GraphPad Prism 5.0
tool. Paired samples comparison and correlation analysis between
miRNAs expression in Fresh/Frozen and FFPE-dissected samples
were performed using Wilcoxon paired test and Spearman
Figure 3. Comparison between miRNAs expression profile in Fresh/Frozen and in FFPE specimens. a) Example of one specimen with a
good correlation of miRNAs expression profile obtained in Fresh/Frozen (pointed line) and in FFPE specimen (squared line); b) Example of one specimen
with a correlation less than r,0.65 of miRNAs expression profile obtained in Fresh/Frozen (pointed line) and in FFPE specimen (squared line).
doi:10.1371/journal.pone.0035596.g003
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correlation respectively. Level of significance was p,0.05 for all
the statistical analysis.
Results
Distribution for Fresh/Frozen (FF) and FFPE samples was
found not normal, as demonstrated by the Shapiro Test
(p,0.001). For this reason, we only used non-parametric statistical
tests.
A good Spearman correlation value (r = 0.7916, p,0.0001)
between the expression level of each miRNAs comparing results
obtained in fresh-frozen and in FFPE-dissected samples was
observed (Figure 1) whereas Wilcoxon paired test showed not
significant differences between the two groups (p = 0.1845).
To test if the miRNAs profile obtained in Fresh/Frozen and
FFPE-dissected (FD) samples were comparable, we calculated the
median fold-change for each 30 FF samples versus 30 FD
specimens. Although miR-137, miR-20a and miR-21 were slightly
downregulated (FD/FF ratio ,22.0), the vast majority of
miRNAs were not statistically significantly different (Figure 2)
Comparison of individual miRNAs expression between Fresh/
Frozen and FFPE-dissected sample, in single paired specimen,
showed a good Spearman correlation value (r.0.65) in 25 out of
30 samples (Figure 3a) while the remaining five cases showed a
correlation ratio ,0.65 (ranged from 0.5123 to 0.6386, Figure 3b).
To investigate if discrepancy observed in the 5 cases with r,0.65
could be caused by enrichment in neoplastic cells due to dissection,
we analysed the miRNAs profiles of these 5 samples starting from
undissected FFPEmaterial. We performed the analysis only in the 4
cases in which the H&E revealed the presence of not-neoplastic
tissue adjacent the area dissected for miRNAs analysis (Table 3). In
3 out of 4 cases analysed the Spearman correlation value increased
up the cut off of 0.65 (Table 3).
Discussion
The use of formalin-fixed paraffin embedded samples for
nucleic acid analysis in molecular study gives more disposal of
specimen for research. For this reason, miRNAs analysis starting
from FFPE samples could be of great usefulness for miRNAs
expression study. Due to their short length (19–25 nt), the mature
miRNAs seem not to be influenced by nucleic acid degradation
caused by formalin fixation [29], as happened on the contrary for
long RNA or DNA. Several papers reported the feasibility of
miRNAs expression from FFPE specimens in different tissues as
kidney, prostate and breast [32,33,35–38].
GBM is the most aggressive adult brain tumour and,
nevertheless the progresses in molecular therapy, its prognosis
remains very poor [8]. Identifying a miRNAs profile for GBM
could be very useful for better clarify prognosis and researching
new targeted drugs. For this reason, and for ‘‘opening’’ the
anatomic pathology archives even to analysis of miRNAs
expression in GBM, it is crucial determining if FFPE specimens
are suitable for this type of analysis.
Our study demonstrated, in a cohort of 30 paired GBM, that
miRNAs analysis using real-time technique could be performed
starting from FFPE samples as well as from Fresh/Frozen
specimens. The data demonstrated that there is a good correlation
(r = 0.7916) between the profiles obtained starting from FFPE-
dissected samples and from fresh samples.
The real cellular composition of Fresh/Frozen sample is not well
known, in fact, even if a 4 mm-thick snap-frozen section was used for
evaluating fresh sample, the miRNAs extraction was performed
starting from 50–80 mg of not morphologically checked tissue
(containing, for example, lymphocytes or non-neoplastic cells). This
situation could lead to discrepant results in miRNAs analysis that we
observed in 5 out of 30 cases here analysed. In FFPE-dissected
samples, the selection of area used for performing the analysis lead
to enrich the sample in neoplastic cells, avoiding ‘‘contamination’’
due to non-tumoural components. In 3 out of 4 cases, with a not
good (r,0.65) Spearman correlation value, the analysis of miRNAs
expression performed without dissection resulted in a better
correlation with corresponding Fresh/Frozen samples. In only
one case the correlation coefficient value remained below 0.65, even
when obtained without dissecting the sample. To our knowledge,
this sample did not show peculiar histological features (i.e.
predominant lymphocytic infiltrate or necrotic zone).
To the best of our knowledge, this is the first study comparing
the miRNAs expression analysis in GBM in FFPE-dissected
samples and Fresh/Frozen specimens.
Our data demonstrated that in a cohort of 30 GBM, as
happened in other tissues, data of miRNAs expression analysis are
comparable starting from FFPE sample as well as from Fresh/
Frozen specimens. This approach have several advantages: it is
possible to check the real composition of the analysed sample, and
it could be possible to dispose of archival material for miRNAs
expression analysis (even considering the difficult to retrieve fresh
brain tissue). The fact that dissection could influence the
expression results leads to put a lot of attention in comparing
miRNAs analysis performed with or without dissection.
Table 3. Spearman correlation values between miRNA profiles obtained in Fresh/Frozen, FFPE-dissected and FFPE-not dissected
samples.
Case
R (Fresh/Frozen vs FFPE-
dissected)
R (Fresh/Frozen vs FFPE-not
dissected) Composition of not-dissected FFPE sample
Neoplastic cells (%) Not-neoplastic cells (%)
1 0.51 NP 98 2
2 0.60 0.70 50 50
3 0.50 0.38 75 25
4 0.62 0.81 70 30
5 0.63 0.89 40 60
NP: Not Performed.
doi:10.1371/journal.pone.0035596.t003
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Abstract
Glioblastoma is the most aggressive brain tumor that may occur in adults. Regardless of the huge improvements in surgery
and molecular therapy, the outcome of neoplasia remains poor. MicroRNAs are small molecules involved in several cellular
processes, and their expression is altered in the vast majority of tumors. Several studies reported the expression of different
miRNAs in glioblastoma, but one of the most critical point in understanding glioblastoma miRNAs profile is the comparison
of these studies. In this paper, we focused our attention on the non-neoplastic references used for determining miRNAs
expression. The aim of this study was to investigate if using three different non-neoplastic brain references (normal adjacent
the tumor, commercial total RNA, and epileptic specimens) could provide discrepant results. The analysis of 19 miRNAs was
performed using Real-Time PCR, starting from the set of samples described above and the expression values compared.
Moreover, the three different normal RNAs were used to determine the miRNAs profile in 30 glioblastomas. The data
showed that different non-neoplastic controls could lead to different results and emphasize the importance of comparing
miRNAs profiles obtained using the same experimental condition.
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Introduction
MicroRNAs (miRNAs) are small RNA molecules involved in
several cellular processes. Briefly, these small RNAs regulate
proteins expression by binding target mRNAs with a perfect or
imperfect complementarity [1]. The miRNAs expression analysis
could be performed using different techniques, such as microarray
assays or Real-Time PCR. Regardless of the chosen approach, one
of the most important decisions before analyzing miRNAs profile
(as well as for mRNAs expression studies) is the selection of a
reference control. The availability of non-neoplastic specimens
used as reference is often subordinated to understudied tissue.
Differently from what happens for other tissues such as breast or
lung [2–4], obtaining brain specimens from healthy subjects is very
difficult and, therefore, finding a suitable non-neoplastic control
for the analysis of RNA in brain neoplasia still remains a big issue.
Moreover, for surgical neoplastic brain samples, the non-
neoplastic area is usually absent, very limited, or adjacent the
tumor, as for glioblastoma (GBM).
This study was conducted within the PERNO (Progetto
Emiliano-Romagnolo di Neuro-Oncologia) project. One of the
goals of PERNO is to investigate the role of miRNAs in GBM. In
a previous paper [5], we demonstrated the feasibility of miRNAs
analysis in brain specimens starting from formalin-fixed and
paraffin-embedded tissues (FFPE), as well as in fresh/frozen
samples. In literature, there are at least three different specimens
used as normal reference for miRNAs analysis in brain samples:
the normal area adjacent the tumor [6–8], one of the available
commercial references (FirstChoiceH Human Brain Reference
RNA, Ambion) [9,10], and the tissue removed in epileptic patients
[11,12]. Before looking for miRNAs profile in GBM, we decided
to deeply investigate the miRNAs expression values in these three
different non-neoplastic RNAs.
The aim of this study was to compare three different references
used as non-neoplastic control for miRNAs analysis in GBM (the
normal area adjacent the tumor, a commercial reference, and the
tissue removed in epileptic patients) by investigating the expression
levels of nineteen miRNAs. In order to clarify if the choice of non-
neoplastic samples could influence the miRNAs analysis in GBM,
the miRNAs profiles of thirty GBMs were also investigated using
each one of the three references as control.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e55314
Materials and Methods
Ethic Statement
The study was approved by Ethic Committee of Azienda
Sanitaria Locale di Bologna (number of study 08075, protocol
number 139/CE of 5th February 2009, Bologna, Italy). All patients
signed a written consent for molecular analysis and anonymous
data publication for scientific studies, and all information
regarding the human material used in this study was managed
using anonymous numerical codes.
Selection of Cases
MicroRNAs expression analysis was performed using a com-
mercial brain reference (FirstChoiceH Human Brain Reference
RNA, Ambion, Austin, TX, USA), 15 cases of normal samples
adjacent the tumor and 15 cases of polar temporal cortical (PTC)
specimens removed in patients submitted to surgery (tailored polar
anterior temporal resection along with uncus-amygdalohippocam-
pectomy) for drug-resistant epilepsy. All the cases were retrieved at
Bellaria Hospital (Section of Pathology, Bologna, Italy), and
normal samples adjacent the tumor specimens were included
within the PERNO project.
Normal adjacent the tumor. Normal adjacent the tumor
tissues were retrieved at a distance between 1 and 2 cm from the
margin of 15 primary FFPE GBMs. Patients were 8 males and 7
females, aged 50 to 75 years (mean 62.7 yrs). All samples were
diagnosed as GBM according to the 2007 WHO criteria [13].
Thirty samples were also used for the GBMs profile (see below).
Commercial reference. The FirstChoiceH Human Brain
Reference RNA from Ambion was used. According to the
manufacturers’ data sheet, it was obtained from several normal
brain regions (meaning free of brain pathology) of 23 donors, 13
males and 10 females, aged 23 to 86 (mean 69.7 yrs). FirstChoiceH
is certified to contain small RNAs, including miRNAs.
Epileptic tissue. Fifteen FFPE PTC samples were randomly
selected. Epileptic patients were 7 males and 8 females, aged 25 to
52 years (mean 39.7 yrs). All of them presented drug-resistant
anteromedial temporal lobe epilepsy. Histologically, eleven cases
showed focal cortical dysplasia while four patients had hippocam-
pal sclerosis. None of them were affected by a neoplastic lesion,
including GBM. The tissue used for miRNAs extraction was taken
from the temporal lobe cortex.
Glioblastoma. Thirty patients were selected for determining
GBMs profile using the three different non-neoplastic references.
All specimens were primary GBMs, and patients had not
undergone neoadjuvant therapy before surgery. Patients were 14
males and 16 females, aged 42 to 75 years (mean 63.3 yrs). All
samples were diagnosed as GBM according to the 2007 WHO
criteria [13].
miRNAs Analysis
The hematoxylin and eosin (H&E) sections were reviewed by a
pathologist (GM) to select the more informative block. Four 20
mm-thick sections were cut, followed by one H&E control slide.
The area selected for the analysis was marked on the control slide
to ensure, whenever possible, greater than 90% content of glial
cells (normal adjacent the tumor and epileptic specimens) or
neoplastic cells (glioblastoma samples).
Nineteen miRNAs (miR-7, miR-9, miR-9*, miR10a, miR10b,
miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-
34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330,
miR-519d) were studied according to their role in GBM and
because of their previous technical validation in order to
determine the feasibility of analysis starting from FFPE tissues
[5]. Three small RNAs (RNU49, U54, miR-103) were used as
internal control [5]. The miRNAs extraction and analysis were
performed as previously described [5]. Briefly, RNA was retro-
transcribed using the NCode miRNA First-Strand cDNA Synthe-
sis and qRT-PCR Kits (Invitrogen, Carlsbad, CA, USA), and
miRNAs expression was evaluated using an AB7000 machine
(Applied Biosystem, Foster City, CA, USA). Each miRNA was run
twice per each sample. Considering that commercial reference was
a pool of RNA obtained from normal brain, it was analyzed three
times (technical replicates).
Statistical Analysis
Expression values and fold changes were obtained by relative
quantification and 22DDCT method [14] using the DataAssist 2.0
Tool (Applied Biosystem, Foster City, CA, USA). In order to
determine miRNAs profile obtained in GBM, the median fold-
change of each miRNA in the 30 GBM samples was compared
with ‘‘control samples’’ (15 epileptic specimens, 14 normal
adjacent tissues and 1 commercial reference). A GBM/Control
ratio ,22.0 means that miRNA was downregulated, while a ratio
$2.0 means that miRNA was upregulated. Statistical analysis of
miRNAs expression was performed using GraphPad Prism 5.0
tool. Gaussian distribution was evaluated by Shapiro-Wilk Test.
Correlation analysis between miRNAs expression in the three
different groups were performed using Spearman correlation test.
For comparing the expression levels of each miRNA obtained in
the three groups, Kruskal-Wallis and Mann-Whitney tests were
used. Level of significance was p,0.05 for all the statistical
analysis.
Results
All the samples, except one normal adjacent the tumor
specimen, gave sufficient quantity of miRNAs for performing the
analysis.
miRNAs Analysis in Normal References
Distribution for normal adjacent the tumor, commercial
reference, and epileptic groups was not Gaussian as demonstrated
by the Shapiro Test (p,0.001). For this reason, we used non-
parametric statistical tests.
All Spearman correlation values between the expression levels
of each miRNAs obtained in the three groups were above 0.65
(p,0.0001) (Table 1).
While comparing the median expression values obtained in the
three different groups, we observed statistical significant differ-
ences (p,0.05) in 9 miRNAs: miR-7, miR-9, miR-10a, miR-10b,
miR-26a, miR-27a, miR-31, miR-137, and miR-182. For the
others, no significant differences were observed (Table S1).
Moreover, the Mann-Whitney test, performed considering groups
in pairs, revealed statistical significant differences even in miR-101
and miR-519d, as shown in Figure 1. It should be considered that
the variability observed in normal adjacent the tumor and in
epileptic specimens is a biological variability, while the one
observed in commercial reference (a pool of normal brain RNA) is
a technical variability.
GBM Profile
The differences observed when comparing expression values of
miRNAs in the three different references led us to further
investigate if the choice of non-neoplastic control could give
discrepant results in analyzing GBM miRNAs profile. For this
reason, we compared the profile of the 19 miRNAs in thirty GBMs
matched with the three different non-neoplastic brain references
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(normal adjacent the tumor, commercial reference, and epileptic
tissue).
Using different non-neoplastic reference groups resulted in
different GBM miRNAs expression profiles (Table 2 and
Figure S1). For example, miR-17 was up-regulated (FC $2.0) in
GBM when matched with Ambion reference, but was not
deregulated when matched with normal adjacent the tumor or
epileptic tissue; miR-31 was down-regulated (FC,22.0) in GBMs
matched with Ambion reference and normal adjacent the tumor,
but not deregulated when matched with epileptic tissue. Other
miRNAs with different expression status were miR-10a, miR-10b,
miR-20a, miR-26a, miR-27a, miR-34a, miR-101, miR-182, miR-
221, miR-222, and miR-330, as shown in Table 2.
The remnant miRNAs (miR-7, miR-9, miR-9*, miR-21, miR-
137, miR-519d) showed the same expression profile in the three
groups even if differences in the level of up- or down-regulation
could be observed (Table 2).
Discussion
GBM is the most aggressive brain tumor that may occur in
adults. Nevertheless, there were improvements in surgery,
radiotherapy, chemotherapy, and ‘‘target therapy’’ [15], while its
prognosis remains poor [13,16]. MicroRNAs expression seems to
play an important role in cancer development and progression and
could be a possible target for molecular therapy [17]. For this
reason, identifying a miRNAs profile in GBM could be very useful
in developing new drugs and therapeutic approaches. The starting
material and samples used as reference control are two crucial
points for expression study design. In a previous study, the authors
demonstrated that miRNAs analysis in GBM is feasible in FFPE
samples, as well as in fresh/frozen ones [5]. Due to the difficulty of
gathering non-neoplastic brain specimens, in literature, there are
Table 1. Spearman correlation values between three groups
(p,0.0001).
Normal Adjacent
Tumor
Ambion Brain
Reference
Epileptic
Tissue
Normal Adjacent Tumor / 0.724 0.702
Ambion Brain Reference 0.724 / 0.848
Epileptic Tissue 0.702 0.848 /
doi:10.1371/journal.pone.0055314.t001
Figure 1. Differences in miRNAs expression. Scatter plots show miRNAs significantly different between groups. Bars indicate median values. *
p,0.05, ** p,0.01 according to Mann-Whitney test. The representation of commercial reference (a pool of normal brain RNA) indicates technical
variability, while scatter plots of Normal adjacent the tumor and epileptic specimens show individual variability. N-Ad, Normal adjacent the tumor;
Ref, Commercial reference; EP, epileptic.
doi:10.1371/journal.pone.0055314.g001
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different samples chosen as reference control in miRNAs
expression analysis (e.g. normal adjacent tissues [6–8] or epileptic
samples [11,17]). Moreover, several commercial pools of RNAs
obtained from normal brain tissues were available, such as the
Ambion FirstChoiceH Human Brain Reference RNA [6,16]. This
situation led each group to arbitrarily choose a reference,
sometimes obtaining different miRNAs expression profiles accord-
ing to selected control [18].
In our study, we investigated if miRNAs expression profiles
obtained using different non-neoplastic controls are comparable or
not. For this reason, normal samples adjacent the tumor,
commercial reference (FirstChoiceH Human Brain Reference
RNA – Ambion), and epileptic samples were used. Although
microarrays are a widescreen and powerful method for miRNAs
analysis, we focused on the 19 miRNAs previously analyzed and
validated in order to determine the feasibility of analysis starting
from both fresh frozen and FFPE tissues [5].
Before analyzing miRNAs expression data, some technical
issues regarding the present study should be considered. The mean
age of the epileptic group was significantly different from that of
the others, as expected considering mean age of epilepsy onset.
The commercial reference was a pool of RNAs obtained from
multiple donors and several brain regions, while RNAs from other
non-neoplastic groups (normal adjacent tissue and epileptic
specimens) were not pooled together; for this reason, the replicates
obtained from commercial reference represented technical repli-
cates, while those obtained from the other groups were evaluated
as biological replicates. Bearing in mind these issues, it should be
considered that the aim of the present study was to determine
whether GBM miRNAs profile shows differences using several
non-neoplastic references. For this reason we reproduced three
experimental conditions with normal adjacent tissues, commercial
references or epileptic specimens as non-neoplastic controls.
The comparison between expression values of miRNA obtained
in each of the three groups revealed good correlation values
(.0.65). However, the correlation value was higher when
comparing epileptic and commercial reference (R: 0.848).
Meanwhile, when epileptic group and commercial reference were
compared with normal adjacent the tumor, the correlation values
were lower (R: 0.702 and 0.724, respectively). This could be due to
the fact that the miRNAs expression profile of normal adjacent the
tumor tissue could be influenced by the surrounding neoplastic
cells, just as what happened during mRNA expression analysis
experiments [19].
While comparing the median expression values of each
miRNAs obtained in the three different groups, we observed
some statistical significant differences (p,0.05) in several miRNAs
(miR-7, miR-9, miR-10a, miR-10b, miR-26a, miR-27a, miR-31,
miR-101, miR-137, miR-182, miR-519d).
Bearing in mind this evidence, we analyzed 19 miRNAs in a
group of GBMs (thirty samples within the PERNO project cohort)
using the three previously described references as non-neoplastic
controls. We observed that miRNAs profiles obtained in these 30
GBMs were different according to the chosen control group. In
fact, no differences were observed in 6 miRNAs, while 13 out of 19
(miR-10a, miR-10b, miR-17, miR-20a, miR-26a, miR-27a, miR-
31, miR-34a, miR-101, miR-182, miR-221, miR-222, and miR-
330) showed a different modulation in GBM depending on a
selected reference, considering a cutoff of 2-fold change. More-
over, it should be noticed that, even in those miRNAs showing a
Table 2. MiRNAs profile in 30 GBMs compared with the 3 different non-neoplastic references.
miRNAs Normal adjacent Tumor Ambion Reference Epileptic
Median FC 6
Median Error Statusa N. of casesb
Median FC 6
Median Error Statusa N. of casesb
Median FC 6
Median Error Statusa N. of casesb
miR-7 27.37760.257 DOWN 24/30 211.08660.117 DOWN 27/30 223.75360.055 DOWN 28/30
miR-9 1.67960.671 = 14/30 21.40360.194 = 18/30 21.33160.290 = 20/30
miR-9* 1.85561.509 = 14/30 1.68460.936 = 18/30 1.52160.884 = 18/30
miR-10a 1.29660.494 = 16/30 1.07460.280 = 18/30 2.43660.954 UP 19/30
miR-10b 1.84461.111 = 9/30 3.10561.157 UP 21/30 4.68862.699 UP 23/30
miR-17 1.66061.620 = 18/30 2.03861.358 UP 16/30 1.96061.360 = 14/30
miR-20a 2.39660.729 UP 18/30 1.60660.334 = 18/30 2.21760.501 UP 17/30
miR-21 10.18063.602 UP 27/30 9.69462.343 UP 27/30 13.61465.270 UP 28/30
miR-26a 1.08061.346 = 21/30 25.97460.143 DOWN 28/30 21.45060.964 = 19/30
miR-27a 1.41960.339 = 22/30 2.99560.489 UP 23/30 2.92360.764 UP 23/30
miR-31 23.14260.775 DOWN 19/30 28.83861.471 DOWN 25/30 21.89161.041 = 11/30
miR-34a 1.02960.674 = 15/30 2.20560.983 UP 15/30 1.92861.481 = 14/30
miR-101 21.11660.675 = 20/30 22.46660.209 DOWN 18/30 22.65660.241 DOWN 19/30
miR-137 23.68160.075 DOWN 24/30 26.17560.031 DOWN 29/30 210.92960.308 DOWN 29/30
miR-182 21.04961.394 = 12/30 1.92461.923 = 11/30 4.73761.756 UP 21/30
miR-221 21.43160.951 = 15/30 21.26760.733 = 14/30 22.53260.447 DOWN 18/30
miR-222 210.23060.194 DOWN 26/30 21.98260.674 = 10/30 212.98760.152 DOWN 28/30
miR-330 24.76560.228 DOWN 24/30 21.71560.432 = 14/30 25.88260.156 DOWN 24/30
miR-519d 24.81360.238 DOWN 22/30 23.55260.220 DOWN 20/30 22.42160.326 DOWN 17/30
aStatus is determined according to Median Fold Change; b Number of GBMs showing the modulation out of a total of 5. FC: Fold change; UP: up-regulated (FC $2.0);
DOWN: down-regulated (FC ,22.0); = : not deregulated.
doi:10.1371/journal.pone.0055314.t002
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comparable status in the three groups, differences in fold change
values can be observed (e.g. miR-7, miR-137).
The differences in expression of some miRNAs in comparison
with other studies could be due to: 1) the enrichment in neoplastic
cells could give discrepant results with those obtained without
performing dissection [5]; 2) different reference controls could lead
to different miRNAs profiles as demonstrated in this study. An
example was the study by Malzkorn et al. [10] in which miR-9,
miR-17, miR-20a, and miR-21 showed an increased expression in
recurrent GBMs compared with primary grade II tumors.
Although a splendid approach and technique were used in the
study, it is not advisable to compare these results with ours, both in
agreement (e.g. mir-20a) and not (e.g. miR-9), because of a
different reference (primary grade II tumors) used by Malzkorn
et al. for determining the modulation of selected miRNAs.
Even though only 19 miRNAs were here considered, it is
reasonable to hypothesize that the same discrepancies could be
observed analyzing any miRNAs.
In conclusion, the present study shows that comparing miRNAs
profiles obtained using different non-neoplastic controls is not
recommended for several reasons: 1) the physiological differences
in mean age that could be observed between different groups (e.g.
epileptic specimens have a mean age lower than normal adjacent
the tumor samples); 2) technical issues: e.g. a commercial reference
is usually obtained pooling together several non-neoplastic RNAs
(technical variability), while RNAs obtained from normal adjacent
the tumour or epileptic specimens are not usually pooled together
(biological variability); 3) different selected non-neoplastic groups
could have real different miRNAs expression values. Having
considered that the number of GBMs analyzed in this study was
too small for determining a conclusive miRNAs profile (study in
progress), we emphasized that the results of miRNAs profile in
GBMs are strictly dependent on the non-neoplastic reference.
Supporting Information
Figure S1 miRNAs profile in 30 GBMs compared with the three
different non-neoplastic references. Lines in correspondence of
Median FC = +2 and 22 indicate the cut off for up- or down-
regulation, respectively. Bars indicate FC median errors. FC, Fold
change; N-Ad, Normal adjacent the tumor; Ref, Commercial
reference; EP, epileptic.
(TIF)
Table S1 Median expression values obtained in the three
different groups. *p-values were obtained using Kruskal-Wallis
test.
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